<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1658536</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2025.1658536</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Identify the therapeutic role and potential mechanism of &#x3b1;-cyperone in diminished ovarian reserve based on network pharmacology, molecular docking, Lip-MS and experimental validation</article-title>
<alt-title alt-title-type="left-running-head">Guo et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1658536">10.3389/fphar.2025.1658536</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Jingwen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3120811"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Xitang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Xue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2824724"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hu</surname>
<given-names>Rong</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Guo</surname>
<given-names>Hua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Department of Gynecology, General Hospital of Ningxia Medical University</institution>, <city>Yinchuan</city>, <state>Ningxia</state>, <country country="CN">China</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>The First Clinical Medical College, Ningxia Medical University</institution>, <city>Yinchuan</city>, <state>Ningxia</state>, <country country="CN">China</country>
</aff>
<aff id="aff3">
<label>3</label>
<institution>Ningxia Key Laboratory of Clinical and Pathogenic Microbiology, General Hospital of Ningxia Medical University</institution>, <city>Yinchuan</city>, <state>Ningxia</state>, <country country="CN">China</country>
</aff>
<aff id="aff4">
<label>4</label>
<institution>Reproductive Medicine Center, General Hosptial of Ningxia Medical University</institution>, <city>Yinchuan</city>, <state>Ningxia</state>, <country country="CN">China</country>
</aff>
<aff id="aff5">
<label>5</label>
<institution>Ningxia Key Laboratory of Stem Cells and Regenerative Medicine, Ningxia Medical University</institution>, <city>Yinchuan</city>, <state>Ningxia</state>, <country country="CN">China</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: Rong Hu, <email xlink:href="mailto:hur@nyfy.com.cn">hur@nyfy.com.cn</email>; Hua Guo, <email xlink:href="mailto:1321766393@qq.com">1321766393@qq.com</email>
</corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-15">
<day>15</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1658536</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>07</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>25</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Guo, Yang, Chen, Hu and Guo.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Guo, Yang, Chen, Hu and Guo</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-15">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>The presence of diminished ovarian reserve (DOR) poses a significant threat to female fertility, with no current effective treatment available. Inflammation plays pivotal roles in the pathogenesis of DOR. &#x3b1;-Cyperone (AC) exhibits notable anti-inflammatory and anti-oxidative properties; however, its potential for improving DOR remains unexplored.</p>
</sec>
<sec>
<title>Methods</title>
<p>The PubChem, PharmMapper, and SwissTargetForecast databases were queried to retrieve biochemical information and drug targets for AC. The identification of disease targets for DOR involved referring to the OMIM and Genecards databases. AC&#x2019;s therapeutic targets against DOR were determined by examining the overlap between drug targets and disease targets. To analyze GO function enrichment, KEGG pathway, and disease association, the Metascape database was utilized. The results were then visualized using Cytoscape software. Receptor-ligand interaction between AC and target sites was validated through molecular docking investigations utilizing Pymol and AutoDock program software. The effect of AC on granule cell function was verified in CTX-induced DOR granule cell model. The actual AC-binding proteins in the cells were identified by Lip-MS, and the effects of AC on target protein genes were verified by RT-qPCR.</p>
</sec>
<sec>
<title>Results</title>
<p>Following the integration of 466 drug targets with 1,529 disease targets, we identified 257 AC targets for the treatment of DOR. We recorded the top 20 enriched biological processes, molecular functions, and KEGG pathways that potentially contribute to the anti-DOR effect of AC. Employing the MCC algorithm, we identified key TOP22 proteins. The docking studies revealed that AC binds strongly to all 22 proteins studied. The CTX-induced DOR granule cell model was successfully established, which was verified by detecting the levels of AMH, ROS, MMP and cell viability, indicating that AC enhanced the function of DOR granule cells. The abnormal expression patterns of MAP2K1, AKT1, ESR2, ERBB2, CDH1, CYP19A1, ESR1 and MAPK8 genes were also reversed. In addition, the binding of AC to MAP2K1, GSK3B and MAPK14 was verified by Lip-MS experiments.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>AC can improve CTX-induced KGN proliferation and improved the function of KGN cell. The mechanism may be due to the targeted binding ability of AC to domains of MAP2K1, MAPK14 and GSK3B. AC&#x2019;s potential therapeutic targets are comprehensively explored in this study, as well as theoretical support for its use in the treatment of DOR is provided.</p>
</sec>
</abstract>
<kwd-group>
<kwd>&#x3b1;-cyperone</kwd>
<kwd>diminished ovarian reserve</kwd>
<kwd>network pharmacology</kwd>
<kwd>molecular docking</kwd>
<kwd>experimental validation</kwd>
<kwd>limited proteolysis&#x2013;mass spectrometry</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. The present study was supported by Key research and development project of Ningxia Hui Autonomous Region (Grant Nos. 2025BEG02004 and 2025BEG02003), National Natural Science Foundation of China (NSFC) [Grant No. 82160293], The talent Introduction Special Project of Key project of Ningxia Natural Science Foundation (Grant No. 2024BEH04162), Central Guidance Fund for Local Science and Technology Development of China (Grant No. 2024FRD05140), Open Project of the Key Laboratory of Stem Cells and Regenerative Medicine of Ningxia Hui Autonomous Region (Grant No. KF202408).</funding-statement>
</funding-group>
<counts>
<fig-count count="7"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="65"/>
<page-count count="18"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Experimental Pharmacology and Drug Discovery</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<label>1</label>
<title>Introduction</title>
<p>Diminished ovarian reserve (DOR) is a pathological state characterized by the gradual decline in both quantity and quality of oocytes, making it a common age-associated condition affecting female reproductive health. It accounts for around 20% of all ovarian illness (<xref ref-type="bibr" rid="B24">Jiao et al., 2021</xref>; <xref ref-type="bibr" rid="B40">Practice Committee of the American Society for Reproductive, 2012</xref>). This condition significantly impacts women&#x2019;s fertility potential and overall wellbeing, exerting substantial implications on their reproductive health and overall quality of life.</p>
<p>Accumulating evidence has suggested that the pathogenic mechanism of DOR is associated with several elements, including advanced age, enetic predisposition, infections, immune, environmental factors and iatrogenic causes (<xref ref-type="bibr" rid="B30">Li et al., 2023</xref>; <xref ref-type="bibr" rid="B14">Greene et al., 2014</xref>; <xref ref-type="bibr" rid="B17">He et al., 2023</xref>). However, even after excluding these risk factors, the etiology of DOR remains unknown in some patients. Recent studies have demonstrated that chronic aseptic inflammation and oxidative stress play pivotal roles in the development of DOR (<xref ref-type="bibr" rid="B37">Luderer, 2014</xref>; <xref ref-type="bibr" rid="B52">Snider and Wood, 2019</xref>; <xref ref-type="bibr" rid="B10">de Souza et al., 2015</xref>; <xref ref-type="bibr" rid="B48">Senates et al., 2013</xref>). The findings revealed significantly elevated levels of inflammatory markers in both serum and follicular fluid among DOR patients compared to healthy women (<xref ref-type="bibr" rid="B61">Yang et al., 2018</xref>). The aforementioned suggests that the inflammatory state of the follicular microenvironment may have an impact on oocyte quality. It has been shown that increased inflammation of granulosa cells within the follicle is negatively correlated with oocyte quality. Intra-follicular TNF-&#x3b1; has been found to potentially enhance IL-1 and IL-6 secretion by up-regulating the NF-&#x3ba;&#x3b2; pathway in granulosa cells, consequently leading to a reduction in oocyte quality (<xref ref-type="bibr" rid="B29">Li et al., 2019</xref>). Previous research has suggested that individuals with DOR exhibited notably elevated levels of NLRP3, IL-1&#x3b2;, and caspase-1 expression in both oocytes and granulosa cells. After inhibiting inflammasome activity, there was a rise in anti-Mullerian hormone (AMH) levels and autophagy rates in the ovaries, leading to noticeable improvement in ovarian function (<xref ref-type="bibr" rid="B43">Navarro-Pando et al., 2021</xref>). Compared to mice with the wild-type genotype, mice lacking TNF-&#x3b1; demonstrate increased multiplication levels in granulosa cells within the ovaries, a decreased incidence of follicular atresia, and improved fertility. These findings suggest that TNF-&#x3b1; plays a crucial role in facilitating ovarian function by controlling apoptosis in granulosa cells (<xref ref-type="bibr" rid="B9">Cui et al., 2011</xref>). In addition, oxidative stress has been found to induce ovarian endocrine dysfunction resulting in compromised oocyte quality along with granulosa cell apoptosis leading to follicular atresia&#x2013;another significant cause for ovarian function impairment (<xref ref-type="bibr" rid="B37">Luderer, 2014</xref>).</p>
<p>Current clinical treatment strategies for DOR encompass hormone replacement therapy, assisted reproductive technology, and lifestyle interventions. However, these approaches are limited in their applicability, cost implications, significant side effects, and potential risks (<xref ref-type="bibr" rid="B23">Jiao and Bukulmez, 2021</xref>), thereby posing a substantial clinical challenge in the treatment of DOR (<xref ref-type="bibr" rid="B64">Zhang et al., 2023</xref>). Considering the current absence of efficacious clinical remedies, it is imperative to expedite the development of pharmaceutical interventions targeting DOR for both preventive and therapeutic purposes.</p>
<p>As a traditional Chinese medicine, Xiangfu (<italic>Cyperi Rhizoma</italic>) has a long history and is widely used in clinic. Modern research has shown that &#x3b1;-Cyperone, which is the main chemical component of <italic>Cyperi Rhizoma</italic>, has exhibited pharmacological activities including antimicrobial, antioxidant, neuroprotective, anti-hemolytic, and anti-inflammatory effects (<xref ref-type="bibr" rid="B56">Taheri et al., 2021</xref>). A research study has shown that &#x3b1;-Cyperone exhibits neuroprotective effects on dopaminergic neurons and reduces neuroinflammation in a rat model of Parkinson&#x2019;s disease induced by LPS. The suppression of the NF-&#x3ba;&#x3b2; signaling pathway and activation of the Nrf2/HO-1 signaling pathway are responsible for accomplishing this (<xref ref-type="bibr" rid="B21">Huang et al., 2023</xref>). According to the study conducted by Xueshibojie L et al., &#x3b1;-Cyperone effectively alleviates acute lung injury induced by LPS in mice by activating SIRT1 through targeting the NF-&#x3ba;&#x3b2; and NLRP3 signaling pathways (<xref ref-type="bibr" rid="B34">Liu et al., 2019</xref>). Xiao-Dong P. et al. Conducted a study which revealed that &#x3b1;-Cyperone has the ability to regulate the PI3K/Akt/mTOR signaling pathway mediated by ROS, resulting in the suppression of HeLa cell proliferation in cervical cancer (<xref ref-type="bibr" rid="B45">Pei et al., 2020</xref>). However, the potential role of &#x3b1;-Cyperone in ovarian protection in DOR has not yet been investigated in either domestic or international studies.</p>
<p>The remarkable advancements in the realm of bioinformatics have given rise to network pharmacology as an influential tool for comprehensively grasping the workings of intricate drug systems. One notable characteristic of traditional Chinese herbal formulations is their ability to simultaneously target numerous pathways, processes, and targets. The core principle of network pharmacology involves utilizing diverse databases to construct interconnected networks that reveal the connections between chemical compounds, drugs, and targets. This method enables the conversion of complex mechanisms related to drugs with multiple components and targets into visually comprehensible graphical representations, simplifying the systematic analysis of interactions between target proteins and the anticipation of molecular mechanisms that underlie Chinese herbal treatments for diseases (<xref ref-type="bibr" rid="B5">Chen et al., 2023</xref>; <xref ref-type="bibr" rid="B19">Huang, 2023</xref>). Many research studies have utilized network pharmacology techniques to understand how drugs work in treating diseases, while also demonstrating the potential of this methodology for accelerating drug discovery and development (<xref ref-type="bibr" rid="B59">Wu et al., 2022</xref>). In addition, chemical proteomics can reveal the direct binding between small molecules and proteins, and is often used to find the action targets of small molecules such as drugs and endogenous metabolites. Traditional chemical proteomics methods have limited the application of probe affinity due to the difficulty in preparation of chemical probes. Limited proteolysis&#x2013;mass spectrometry (LiP&#x2013;MS) is a new class of chemical proteomics method: after the drug binds to the target protein, it will block the restriction site of the protein, and then cause the target protein sequence to be &#x201c;resistant&#x201d; to enzyme digestion, resulting in changes in the sequence and abundance of the peptide product produced by enzyme digestion. Therefore, sequence identification and quantification of protease cleavage products by mass spectrometry can distinguish which protein sequences are binding targets for small molecules. Therefore, the chemical proteomics method based on limited enzyme digestion does not require chemical probe preparation, which is highly operable and can precisely locate the target sequence. (<xref ref-type="bibr" rid="B46">Piazza et al., 2018</xref>).</p>
<p>Considering the role of chronic inflammation and oxidative stress in the pathogenesis of DOR, as well as the widespread utilization of &#x3b1;-Cyperone for its anti-inflammatory and antioxidant properties, we postulate that &#x3b1;-Cyperone may hold significant therapeutic potential in managing reduced ovarian reserve and preserving ovarian function. In this study, we employed network pharmacology and Lip-MS to identify potential targets associated with &#x3b1;-Cyperone&#x2019;s efficacy against DOR, followed by subsequent validation of its underlying mechanism.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2-1">
<label>2.1</label>
<title>Drug targets of AC</title>
<p>The PubChem database is a publicly accessible repository that offers an extensive collection of chemical information at no cost, thereby providing a comprehensive resource for drug discovery endeavors. (<xref ref-type="bibr" rid="B27">Kim, 2016</xref>). Hence, the PubChem database was employed to extract pertinent details regarding AC, aiding in the discovery of potential targets. SwissTargetPrediction, a web-based tool that utilizes both 2D and 3D similarity metrics of known ligands, effectively forecasts target molecules with biological activity (<xref ref-type="bibr" rid="B13">Gfeller et al., 2014</xref>). PharmMapper proves to be a valuable tool for the discovery of promising drug targets. It is an online tool that utilizes reverse pharmacophore matching and allows for compound querying against an internal database containing a model of pharmacophores (<xref ref-type="bibr" rid="B58">Wang et al., 2017</xref>). Potential targets were predicted independently with these two web servers: SwissTargetPrediction (2-D/3-D ligand similarity, probability &#x2265;0.7) and PharmMapper (reverse pharmacophore matching, Z-score &#x2265;0.9). Only proteins identified by both tools were retained, and their gene symbols were standardised with UniProt (<xref ref-type="bibr" rid="B57">UniProt, 2023</xref>).</p>
</sec>
<sec id="s2-2">
<label>2.2</label>
<title>Therapeutic targets for DOR and identification of drug-disease intersection targets</title>
<p>The Genecards database functions as an extensive and reliable collection of annotated data related to genes. (<xref ref-type="bibr" rid="B47">Safran et al., 2010</xref>). It excels in its capacity to comprehensively calculate the relevance score of diseases and genes, enabling it to identify gene-associated diseases with precision. Meanwhile, OMIM (Online Mendelian Inheritance in Man) functions as a highly dependable and current research tool, meticulously elucidating the intricate relationships between human genes and phenotypes (<xref ref-type="bibr" rid="B2">Amberger et al., 2015</xref>). Therefore, DOR-associated genes were extracted from OMIM (curated entries) and GeneCards (relevance score &#x2265;10) by searching the term &#x201c;diminished ovarian reserve&#x201d;. The final AC-versus-DOR target list was generated as the intersection of the two drug-target and two disease-target sets with Venny 2.1, ensuring that only well-supported candidates were analysed further.</p>
</sec>
<sec id="s2-3">
<label>2.3</label>
<title>Establishing a network for the protein-protein interaction (PPI)</title>
<p>To explore the association between overlapping genes, we utilized the STRING database and specified &#x201c;<italic>Homo sapiens</italic>&#x201d; as the species to import the predicted therapeutic targets (<xref ref-type="bibr" rid="B55">Szklarczyk et al., 2021</xref>). A confidence score threshold of &#x2265;0.7 was applied to obtain a Protein-Protein Interaction (PPI) network diagram, which was then exported in TSV format and subsequently refined using Cytoscape 3.10.1 for further analysis (<xref ref-type="bibr" rid="B31">Liang et al., 2024</xref>). The Cytoscape software, an application for visualizing and analyzing network biology (<xref ref-type="bibr" rid="B19">Huang, 2023</xref>), was utilized to calculate node parameters and visualize molecular connections in the network diagram. To isolate significant targets prior hub gene identification, calculate the significant values by using the cytoNCA plugin to assess degree centrality, between centrality and closeness centrality. To investigate the associations among target genes, we utilized the cytoHubba plugin to assess node degree centrality. Afterwards, we chose the top 20 nodes and arranged them in the inner circle for visualization purposes. Lastly, we employed the MCC algorithm to identify and screen the top 20 genes (<xref ref-type="bibr" rid="B7">Chin et al., 2014</xref>).</p>
</sec>
<sec id="s2-4">
<label>2.4</label>
<title>GO and KEGG enrichment</title>
<p>The therapeutic targets identified for treatment of DOR in AC were examined using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology (GO) enrichment analysis. Biological processes (BP), cellular components (CC), and molecular functions (MF) terms were retrieved with the Metascape database (adjusted P &#x3c; 0.01) (<xref ref-type="bibr" rid="B65">Zhou et al., 2019</xref>). To ensure reliability, each target list was simultaneously uploaded to DAVID 6.8 and STRING (<xref ref-type="bibr" rid="B55">Szklarczyk et al., 2021</xref>; <xref ref-type="bibr" rid="B20">Huang da et al., 2009</xref>), only terms recovered by at least two independent platforms and exhibiting identical leading genes were retained. Enrichment results were visualised with bubble plots generated through the bioinformatics web server (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.com.cn">https://www.bioinformatics.com.cn</ext-link>) (<xref ref-type="bibr" rid="B31">Liang et al., 2024</xref>; <xref ref-type="bibr" rid="B12">Gene Ontology, 2015</xref>).</p>
</sec>
<sec id="s2-5">
<label>2.5</label>
<title>Obtained the key 22 targets of &#x3b1;-cyperone for DOR</title>
<p>The STRING database was utilized to import all targets that were enriched in the three pathways related to &#x2018;production of female gametes, response to hormones, and sex differentiation&#x2019;. Subsequently, these targets were imported into Cytoscape 3.10.1 software for network analysis using the MCC algorithm provided by the cytoHubba module. The top 20 key genes were selected again. After merging and eliminating duplicate entries from the two sets of 20 primary objectives acquired, a final collection of 22 crucial targets was obtained for subsequent examination.</p>
</sec>
<sec id="s2-6">
<label>2.6</label>
<title>Molecular docking validation of the binding capacity between AC and targets</title>
<p>The 3-dimensional configuration of the AC molecule was acquired from the PubChem database (<xref ref-type="bibr" rid="B28">Kim et al., 2016</xref>) and transformed into Mol2 format utilizing Open Babel program (<xref ref-type="bibr" rid="B44">O&#x27;Boyle et al., 2011</xref>). The template structures of the target proteins were acquired from the UniProt database (<xref ref-type="bibr" rid="B57">UniProt, 2023</xref>) and RCSB Protein Data Bank (<xref ref-type="bibr" rid="B5">Chen et al., 2023</xref>; <xref ref-type="bibr" rid="B4">Berman et al., 2000</xref>). To prepare the target proteins for further analysis, water molecules and original ligands were removed using Pymol before importing them into AutoDock Tools 1.5.7. Subsequently, hydrogenation, charge calculation, and non-polar hydrogen combination were performed. After determining the Grid Box size and genetic algorithm parameters, molecular docking was performed using AutoDock Vina through CMD command characters. Finally, Pymol was utilized to visualize the results (<xref ref-type="bibr" rid="B19">Huang, 2023</xref>).</p>
</sec>
<sec id="s2-7">
<label>2.7</label>
<title>Cell culture and treatment</title>
<p>The KGN cells used in this study were obtained from Procell Life Science Technology Co., Ltd. for <italic>in vitro</italic> research purposes. The KGN cells were cultured in a culture medium composed of DMEM/F12, which was supplemented with 10% FBS (fetal bovine serum). The culture conditions were maintained at a temperature of 37&#xa0;&#xb0;C in an environment containing 5% CO<sub>2</sub>, and the culture medium was renewed every 2&#xa0;days. Upon reaching approximately 80% confluency and displaying favorable condition, the cells were divided into three groups (n &#x3d; 6 wells per group, three independent passages on different days): The normal control (NC group): complete medium only; CTX model (CTX group): 10&#xa0;&#x3bc;g/mL cyclophosphamide (Sigma, C3250000) dissolved in serum-free DMEM; &#x3b1;-Cyperone (AC group): pre-treated with varying concentrations &#x3b1;-Cyperone (MedChemExpress, HY-N0710) for 6&#xa0;h, followed by 10&#xa0;&#x3bc;g/mL CTX without wash-out. Cyclophosphamide (CTX; C3250000) was purchased from Sigma (United States) and dissolved in DMEM as per manufacturer&#x2019;s instructions. &#x3b1;-Cyperone was purchased from MedChemExpress (HY-N0710, Monmouth Junction, NJ, United States) and dissolved in Methyl sulfoxide (DMSO; Cat&#x23; D8371, Solarbio Life Sciences, Beijing, China), and in the final cultivation system, the content of DMSO should not exceed 0.01%.</p>
</sec>
<sec id="s2-8">
<label>2.8</label>
<title>Cell viability assay (CCK-8)</title>
<p>The KGN cells were cultured in a 96-well plate with a cell concentration of 1 &#xd7; 10<sup>4</sup> cells/mL. Each well was supplemented with 100&#xa0;&#xb5;L of cell suspension. A minimum of three replicate wells were included in each experimental group. The plate was then placed in an incubator set at 37&#xa0;&#xb0;C and enriched with 5% CO<sub>2</sub> until the cells reached approximately 80% confluence. Subsequently, the culture medium of the AC groups was aspirated and gradient concentrations of AC were introduced into the wells, followed by an incubation period of 6&#xa0;hours. CTX (300&#xa0;&#x3bc;M) was subsequently added to each well in both the CTX and AC groups. The cells were incubated for an extra 24&#xa0;h in the culture medium. Next, 10&#xa0;&#xb5;L of CCK-8 enhancement solution (Meilunbio, China) was added to each well and allowed to incubate for 1&#xa0;hour before measuring optical density (OD) at 450&#xa0;nm using a microplate reader according to standard protocols for colorimetric assays.</p>
</sec>
<sec id="s2-9">
<label>2.9</label>
<title>Elisa</title>
<p>Using the AMH assay kit (Nanjing BYabscience technology Co.,Ltd., BY-EH111084), the optical density (OD) at 450&#xa0;nm was read and the concentration of AMH in the supernatant of KGN cells was determined by comparing with the standard curve.</p>
</sec>
<sec id="s2-10">
<label>2.10</label>
<title>ROS levels assay</title>
<p>Intracellular reactive oxygen species (ROS) were quantified using the 2,7-dichlorodihydrofluorescein diacetate (DCFDA) fluorescent probe (Beyotime Biotech, Nanjing, China). A cell suspension containing 2 &#xd7; 10<sup>5</sup> cells was exposed to a 50&#xa0;mM DCFDA solution in pre-warmed PBS for 30&#xa0;min at 37&#xa0;&#xb0;C, following which the fluorescent signal was captured under excitation at 488&#xa0;nm and emission at 525&#xa0;nm.</p>
</sec>
<sec id="s2-11">
<label>2.11</label>
<title>Mitochondrial membrane potential detection</title>
<p>The JC-1 probe was employed to detect mitochondrial depolarization of KGN cells, following the manufacturer&#x2019;s protocol. Briefly, after the indicated treatments, the cells cultured in 6-well plates were incubated with 5&#xa0;&#x3bc;g/mL JC-1 for 20&#xa0;min at 37&#xa0;&#xb0;C. The staining solution was removed and cells were washed with JC-1 staining buffer twice. The distribution and fluorescence intensity of JC-1 monomers and aggregates were visualized by fluorescence microscopy, and the images were assessed using the ImageJ software. Mitochondrial depolarization was evaluated by the decrease in the red/green fluorescence intensity ratio.</p>
</sec>
<sec id="s2-12">
<label>2.12</label>
<title>Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)</title>
<p>The KGN cells in the NC, CTX, and AC groups were subjected to total RNA extraction using an RNA extraction kit (&#x23;G3640-50T, Servicebio). The spectrophotometric analysis was conducted to evaluate the concentration and purity of the extracted RNA, measuring absorbance at 260&#xa0;nm and 280&#xa0;nm. In order to ensure optimal quality, RNA samples with a D(&#x3bb;)260/D(&#x3bb;)280 ratio falling within the range of 1.8&#x2013;2.0 were stored at &#x2212;80&#xa0;&#xb0;C for future utilization. Subsequently, cDNA synthesis was performed using FastKing gDNA Dispelling RT SuperMix (Tiangen Biotech; Beijing; China), followed by PCR amplification on a lightcycler480II Real-time PCR instrument with SYBR Green PCR master mix (&#x23;G3326-05, Servicebio). Meanwhile, the &#x3b2;-actin gene was concurrently assessed as an internal reference in conjunction with the samples. The 2<sup>&#x2212;&#x394;&#x394;CT</sup> method was employed to determine the relative levels of gene expression. All experiments were performed in triplicate parallel assays. The primers utilized in this investigation were custom-designed and synthesized by TsingKe (Wuhan, China), and their specific sequences can be found in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Sequences of PCR primers.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Gene symbol</th>
<th align="center">Forward primer (5&#x2032;&#x2013;3&#x2032;)</th>
<th align="center">Reverse primer (5&#x2032;&#x2013;3&#x2032;)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">&#x3b2;-actin</td>
<td align="center">TAT&#x200b;GCT&#x200b;CTC&#x200b;CCT&#x200b;CAC&#x200b;GCC&#x200b;ATC&#x200b;C</td>
<td align="center">GTC&#x200b;ACG&#x200b;CAC&#x200b;GAT&#x200b;TTC&#x200b;CCT&#x200b;CTC&#x200b;AG</td>
</tr>
<tr>
<td align="center">MAP2K1</td>
<td align="center">CAA&#x200b;TGG&#x200b;CGG&#x200b;TGT&#x200b;GGT&#x200b;GTT&#x200b;C</td>
<td align="center">GAT&#x200b;TGC&#x200b;GGG&#x200b;TTT&#x200b;GAT&#x200b;CTC&#x200b;C</td>
</tr>
<tr>
<td align="center">GSK3B</td>
<td align="center">AGA&#x200b;CGC&#x200b;TCC&#x200b;CTG&#x200b;TGA&#x200b;TTT&#x200b;ATG&#x200b;T</td>
<td align="center">CCG&#x200b;ATG&#x200b;GCA&#x200b;GAT&#x200b;TCC&#x200b;AAA&#x200b;GG</td>
</tr>
<tr>
<td align="center">MAPK14</td>
<td align="center">GCT&#x200b;CTC&#x200b;CAG&#x200b;ACC&#x200b;ATT&#x200b;TCA&#x200b;GT</td>
<td align="center">AAT&#x200b;TCC&#x200b;TCC&#x200b;AGA&#x200b;GAC&#x200b;CTT&#x200b;GC</td>
</tr>
<tr>
<td align="center">SRC</td>
<td align="center">ACT&#x200b;ACT&#x200b;CCA&#x200b;AAC&#x200b;ACG&#x200b;CCG&#x200b;AT</td>
<td align="center">CCC&#x200b;ATC&#x200b;CAC&#x200b;ACC&#x200b;TCG&#x200b;CCA&#x200b;AA</td>
</tr>
<tr>
<td align="center">AKT1</td>
<td align="center">CCT&#x200b;TCA&#x200b;TCA&#x200b;TCC&#x200b;GCT&#x200b;GCC&#x200b;TG</td>
<td align="center">TCC&#x200b;ATC&#x200b;TCC&#x200b;TCC&#x200b;TCC&#x200b;TCC&#x200b;TG</td>
</tr>
<tr>
<td align="center">ESR2</td>
<td align="center">CTC&#x200b;CTT&#x200b;TAG&#x200b;TGG&#x200b;TCC&#x200b;ATC&#x200b;GC</td>
<td align="center">CCC&#x200b;TCT&#x200b;TTG&#x200b;AAC&#x200b;CTG&#x200b;GAC&#x200b;CA</td>
</tr>
<tr>
<td align="center">ERBB2</td>
<td align="center">GCG&#x200b;AGA&#x200b;GGT&#x200b;GAG&#x200b;GGC&#x200b;AGT&#x200b;TA</td>
<td align="center">TCC&#x200b;CCA&#x200b;TCA&#x200b;AAG&#x200b;CTC&#x200b;TCC&#x200b;GGC</td>
</tr>
<tr>
<td align="center">CDH1</td>
<td align="center">GAT&#x200b;AGA&#x200b;GAA&#x200b;CGC&#x200b;ATT&#x200b;GCC&#x200b;AC</td>
<td align="center">GGG&#x200b;TGA&#x200b;ATT&#x200b;CGG&#x200b;GCT&#x200b;TGT&#x200b;TG</td>
</tr>
<tr>
<td align="center">CYP19A1</td>
<td align="center">GCT&#x200b;GGA&#x200b;CAC&#x200b;CTC&#x200b;TAA&#x200b;CAC&#x200b;GC</td>
<td align="center">AGG&#x200b;AGA&#x200b;GCT&#x200b;TGC&#x200b;CAT&#x200b;GCA&#x200b;TC</td>
</tr>
<tr>
<td align="center">ESR1</td>
<td align="center">GGG&#x200b;AAG&#x200b;TAT&#x200b;GGC&#x200b;TAT&#x200b;GGA&#x200b;ATC&#x200b;TG</td>
<td align="center">TGG&#x200b;CTG&#x200b;GAC&#x200b;ACA&#x200b;TAT&#x200b;AGT&#x200b;CGT&#x200b;T</td>
</tr>
<tr>
<td align="center">MAPK8</td>
<td align="center">TCT&#x200b;GGT&#x200b;ATG&#x200b;ATC&#x200b;CTT&#x200b;CTG&#x200b;AAG&#x200b;CA</td>
<td align="center">TCC&#x200b;TCC&#x200b;AAG&#x200b;TCC&#x200b;ATA&#x200b;ACT&#x200b;TCC&#x200b;TT</td>
</tr>
<tr>
<td align="center">PARP1</td>
<td align="center">CGG&#x200b;AGT&#x200b;CTT&#x200b;CGG&#x200b;ATA&#x200b;AGC&#x200b;TCT</td>
<td align="center">TTT&#x200b;CCA&#x200b;TCA&#x200b;AAC&#x200b;ATG&#x200b;GGC&#x200b;GAC</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-13">
<label>2.13</label>
<title>Limited proteolysis&#x2013;mass spectrometry (LiP&#x2013;MS)</title>
<p>This part of the experiment and data analysis were performed by APT Biotechnology (Shanghai, China).</p>
<sec id="s2-13-1">
<label>2.13.1</label>
<title>Protein extraction and enzymatic digestion of peptides</title>
<p>Samples of granulosa cells in the CTX group were collected and homogenized with 1x PBS for protein extraction, and BCA was used for protein quantification. The samples were equally divided, the AC group was treated with 40&#x3bc;M AC, and the CTX group was added with 1.4&#xa0;mM DMSO, to ensure that the DMSO content in both groups is the same, and the final concentration of DMSO in the system should not exceed 0.01%. (<xref ref-type="fig" rid="F7">Figure 7A</xref>). The treated samples were pretreated with 50&#xa0;&#x3bc;g/mL proteinase K (PK enzyme) for 15&#xa0;min and 15ug of protein was subjected to SDS-PAGE. The PK-treated samples were added with denaturing agent (UA/DOC), DTT was added to the final concentration of 20mM, the reaction was performed at 30&#xb0; for 2&#xa0;h, then cooled to room temperature, IAA was added to the final concentration of 25mM, shaking at 600rpm for 1min, and dark room temperature for 30min. The UA/DOC concentration was diluted to below 1.5M by adding an appropriate amount of NH4HCO3 buffer (50&#xa0;mM). Then, 2&#xa0;&#x3bc;g Trypsin was added to the sample and incubated at 37&#xb0; C for 16&#xa0;h. They were desalted and lyophilized and then redissolved in 0.1%FA. Peptide concentration was determined by OD280. Then 2&#xa0;&#x3bc;g of each peptide was removed and incorporated with appropriate amount of iRT standard peptide for DIA mass spectrometry detection.</p>
</sec>
<sec id="s2-13-2">
<label>2.13.2</label>
<title>Mass spectrometry</title>
<p>DIA analysis was performed using a nanoliter flow rate Vanquish Neo system (Thermo Fisher) for chromatographic separation, and samples separated by nanoliter HPLC were subjected to DIA (data independent) mass spectrometry on an Astral high-resolution mass spectrometer (Thermo Scientific). Detection mode: positive ion, parent ion scanning range was 380&#x2013;980m/z, primary mass spectrometry resolution was 240,000&#xa0;at 200&#xa0;m/z, Normalized AGC Target was 500%, and Maximum IT was 5&#xa0;m. MS2 used DIA data acquisition mode, set 299 scanning Windows, Isolation Window was 2m/z, HCD Collision Energy was 25ev, Normalized AGC Target was 500%. The Maximum IT is 3&#xa0;m.</p>
</sec>
<sec id="s2-13-3">
<label>2.13.3</label>
<title>Data analysis</title>
<p>DIA data were processed using Spectronaut software. Software parameters are set as follows: retention time prediction type is set to dynamic iRT, interference on MS2 level correction is enabled, cross run normalization was enabled, and all results had to pass the Q Value cutoff of 0.01 (FDR&#x3c;1%).</p>
</sec>
<sec id="s2-13-4">
<label>2.13.4</label>
<title>Bioinformatics analysis</title>
<p>The quantitative information of the target protein set was first normalized. Then, the Complexheatmap R package (R Version 3.6.3) was used to simultaneously classify the expression of samples and proteins in two dimensions (distance algorithm: Euclidean, connection mode: Average linkage) and generate hierarchical clustering heatmaps. The target protein set was normalized, and the fuzzy c-means (FCM) algorithm of Mfuzz software was used for fuzzy C-means clustering algorithm analysis. According to the expression trend, the protein set was divided into different expression modules to generate different clusters. Protein domain analysis was performed using the Pfam database, and functional characterization of sequences was performed by running scanning algorithms from the InterPro database in an integrated manner using the InterProScan software package, thereby obtaining domain annotation information of target protein sequences in the Pfam database. GO annotation of the set of target proteins was performed using Blast2GO. KAAS (KEGG Automatic Annotation Server) software was used to perform KEGG pathway annotation of the target protein set. Fisher&#x2019;s Exact Test was used to compare each GO category (or KEGG pathway, or GO annotation or (or KEGG pathway, or Domain) annotation enrichment analysis was performed on the target protein set.</p>
</sec>
</sec>
<sec id="s2-14">
<label>2.14</label>
<title>Statistical analysis</title>
<p>Data are expressed as mean &#xb1; SEM of n &#x3d; 18 replicates per condition (six wells per group in each of three independent experiments). Normality was confirmed for every data set by Shapiro&#x2013;Wilk test and homoscedasticity by Brown&#x2013;Forsythe (&#x2265;3 groups) or F-test (2 groups); all P &#x3e; 0.05. Consequently, group means were compared with two-tailed unpaired t-test (two groups) or one-way ANOVA followed by Tukey&#x2019;s HSD (&#x2265;3 groups) in GraphPad Prism nine and R 4.2.0. If either assumption was violated (P &#x2264; 0.05), Welch&#x2019;s correction or Kruskal&#x2013;Wallis test was substituted. Statistical significance was accepted at &#x3b1; &#x3d; 0.05 and denoted &#x2a;p &#x3c; 0.05, &#x2a;&#x2a;p &#x3c; 0.01, &#x2a;&#x2a;&#x2a;p &#x3c; 0.001.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<label>3</label>
<title>Results</title>
<sec id="s3-1">
<label>3.1</label>
<title>Identification of AC drug and DOR targets</title>
<p>The workflow for screening and identifying key targets for AC treatment of DOR is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. The 2D and 3D configurations, along with associated details of AC, as depicted in <xref ref-type="fig" rid="F2">Figure 2A</xref>, were acquired from the PubChem database (PubChem CID:89528182). Pymol was utilized to generate visual representations of the 3D structure. In order to investigate the potential mechanisms underlying the improvement of DOR by AC, we conducted a search for relevant targets of both AC and DOR, followed by standardizing the obtained gene names using information from the UniProt database. In SwissTargetPrediction and Pharmmapper databases, a total of 198 and 267 AC drug targets were identified respectively. After eliminating duplicates, we selected 466 unique drug targets for further analysis. In Genecards and OMIM databases, there were 1,356 and 202 targets associated with DOR respectively. Following the removal of redundant targets, we obtained a total of 1529 DOR-related targets. Given the scarcity of databases dedicated to identifying targets for both AC and DOR, we constructed separate interaction networks linking AC- and DOR-related targets and assigned distinct color codes to the nodes (targets) retrieved from specific websites (<xref ref-type="sec" rid="s13">Supplementary Figure S2</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets of &#x3b1;-Cyperone in the treatment of DOR.</p>
</caption>
<graphic xlink:href="fphar-16-1658536-g001.tif">
<alt-text content-type="machine-generated">Flowchart illustrating a four-step research process. Step 1: Targets prediction using &#x3B1;-Cyperone and Diminished Ovarian Reserve (DOR) databases like PubChem and GeneCards, with a Venn diagram showing overlap. Step 2: Network analysis involving Metascape, STRING, and Cytoscape for enrichment analysis and PPI network visualization. Step 3: Molecular docking validation using UniProt, PDB, AutoDock, and PyMOL, displaying molecular interaction images. Step 4: Experimental validation with Lip-MS and RT-qPCR methods, including graphs of mRNA expression levels for MAP2K1 and GSK3B.</alt-text>
</graphic>
</fig>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Screening and analysis of potential targets of &#x3b1;-Cyperone on DOR. <bold>(A)</bold> 2D and 3D structure of &#x3b1;-Cyperone. <bold>(B)</bold> Venn diagram of the interaction between &#x3b1;-Cyperone-target and DOR-target. <bold>(C)</bold> PPI Network diagram of target genes. &#x201c;&#x3b1;-Cyperone target - DOR targe.</p>
</caption>
<graphic xlink:href="fphar-16-1658536-g002.tif">
<alt-text content-type="machine-generated">Diagram showing the chemical structure of &#x3B1;-Cyperone and a 3D molecular model in section A. Section B features a Venn diagram comparing &#x3B1;-Cyperone and DOR with an overlap, and a network graph illustrating protein interaction. Section C displays a larger network analysis, highlighting significant nodes in varying colors, with an application of the MCC algorithm simplifying the network on the right.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-2">
<label>3.2</label>
<title>Screening and analysis of key targets of AC on DOR</title>
<p>We analyzed the drug targets for AC and compared them with DOR targets to identify potential therapeutic targets for treating DOR with AC. Our analysis resulted in the identification of a total of 257 potential targets (<xref ref-type="fig" rid="F2">Figure 2B</xref>). The protein interaction network of the remaining genes was established by excluding unrelated genes from the STRING database and enhanced using Cytoscape software. The left side of <xref ref-type="fig" rid="F2">Figure 2C</xref> illustrates the construction of the &#x201c;AC target-DOR target&#x201d; network. Subsequently, we applied the MCC algorithm to identify the top 20 genes, as depicted on the right side of <xref ref-type="fig" rid="F2">Figure 2C</xref>, which included AKT1, ESR1, CTNNB1, IGF1R, ERBB2, HSP90AA1, among others. The detailed data regarding the top 20 genes can be found in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Information about 22 key target proteins and their molecular docking results with AC.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Targets</th>
<th align="center">Name</th>
<th align="center">Uniprot ID</th>
<th align="center">PDB ID</th>
<th align="center">Classification</th>
<th align="center">Energy (Kcal/mol)</th>
<th align="center">Ligand efficiency</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">MAP2K1</td>
<td align="center">Dual specificity mitogen-activated protein kinase kinase 1</td>
<td align="center">Q02750</td>
<td align="center">9AY7</td>
<td align="center">Transferase</td>
<td align="center">&#x2212;6.78</td>
<td align="center">&#x2212;0.42</td>
</tr>
<tr>
<td align="center">GSK3B</td>
<td align="center">Glycogen synthase kinase-3 beta</td>
<td align="center">P49841</td>
<td align="center">4AFJ</td>
<td align="center">Transferase</td>
<td align="center">&#x2212;6.35</td>
<td align="center">&#x2212;0.40</td>
</tr>
<tr>
<td align="center">MAPK14</td>
<td align="center">Mitogen-activated protein kinase 14</td>
<td align="center">Q16539</td>
<td align="center">1WBV</td>
<td align="center">Transferase</td>
<td align="center">&#x2212;6.34</td>
<td align="center">&#x2212;0.40</td>
</tr>
<tr>
<td align="center">SRC</td>
<td align="center" style="color:#0A0A0A">Proto-oncogene tyrosine-protein kinase Src</td>
<td align="center">P12931</td>
<td align="center">2H8H</td>
<td align="center">Transferase</td>
<td align="center">&#x2212;6.34</td>
<td align="center">&#x2212;0.40</td>
</tr>
<tr>
<td align="center">AKT1</td>
<td align="center" style="color:#0A0A0A">RAC-alpha serine/threonine-protein kinase</td>
<td align="center">P31749</td>
<td align="center">1UNQ</td>
<td align="center">Transferase</td>
<td align="center">&#x2212;6.25</td>
<td align="center">&#x2212;0.39</td>
</tr>
<tr>
<td align="center">ESR2</td>
<td align="center">Estrogen receptor beta</td>
<td align="center">Q92731</td>
<td align="center">3OLL</td>
<td align="center" style="color:#333333">Hormone receptor</td>
<td align="center">&#x2212;6.11</td>
<td align="center">&#x2212;0.38</td>
</tr>
<tr>
<td align="center">ERBB2</td>
<td align="center" style="color:#333333">Receptor tyrosine-protein kinase erbB-2</td>
<td align="center">P04626</td>
<td align="center">3H3B</td>
<td align="center">Immune system</td>
<td align="center">&#x2212;5.81</td>
<td align="center">&#x2212;0.36</td>
</tr>
<tr>
<td align="center">CDH1</td>
<td align="center" style="color:#0A0A0A">Cadherin-1</td>
<td align="center">P12830</td>
<td align="center">3FF7</td>
<td align="center">Cell adhesion</td>
<td align="center">&#x2212;5.79</td>
<td align="center">&#x2212;0.36</td>
</tr>
<tr>
<td align="center">CYP19A1</td>
<td align="center">Cytochrome P450 19A1</td>
<td align="center">P11511</td>
<td align="center">5JKV</td>
<td align="center">Oxidoreductase</td>
<td align="center">&#x2212;5.65</td>
<td align="center">&#x2212;0.35</td>
</tr>
<tr>
<td align="center">ESR1</td>
<td align="center" style="color:#0A0A0A">Estrogen receptor</td>
<td align="center">P03372</td>
<td align="center">1A52</td>
<td align="center" style="color:#333333">Hormone receptor</td>
<td align="center">&#x2212;5.51</td>
<td align="center">&#x2212;0.34</td>
</tr>
<tr>
<td align="center">MAPK8</td>
<td align="center">Mitogen-activated protein kinase 8</td>
<td align="center">P45983</td>
<td align="center">4YR8</td>
<td align="center">Transferase</td>
<td align="center">&#x2212;5.5</td>
<td align="center">&#x2212;0.34</td>
</tr>
<tr>
<td align="center">PARP1</td>
<td align="center">Poly [ADP-ribose] polymerase 1</td>
<td align="center">P09874</td>
<td align="center">6BHV</td>
<td align="center">Transferase</td>
<td align="center">&#x2212;5.48</td>
<td align="center">&#x2212;0.34</td>
</tr>
<tr>
<td align="center">IGF1R</td>
<td align="center" style="color:#0A0A0A">Insulin-like growth factor 1 receptor</td>
<td align="center">P08069</td>
<td align="center">1IGR</td>
<td align="center" style="color:#333333">Hormone receptor</td>
<td align="center">&#x2212;5.45</td>
<td align="center">&#x2212;0.34</td>
</tr>
<tr>
<td align="center">MMP2</td>
<td align="center">72&#xa0;kDa type IV collagenase</td>
<td align="center">P08253</td>
<td align="center">1CK7</td>
<td align="center">Hyderolase</td>
<td align="center">&#x2212;5.42</td>
<td align="center">&#x2212;0.34</td>
</tr>
<tr>
<td align="center">PPARG</td>
<td align="center">Peroxisome proliferator-activated receptor gamma</td>
<td align="center">P37231</td>
<td align="center">1FM6</td>
<td align="center">Transcription</td>
<td align="center">&#x2212;5.32</td>
<td align="center">&#x2212;0.33</td>
</tr>
<tr>
<td align="center">HSP90AA1</td>
<td align="center" style="color:#0A0A0A">Heat shock protein HSP 90-alpha</td>
<td align="center">P07900</td>
<td align="center">3K99</td>
<td align="center">Chaperone</td>
<td align="center">&#x2212;5.26</td>
<td align="center">&#x2212;0.33</td>
</tr>
<tr>
<td align="center">PIK3CA</td>
<td align="center">Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform</td>
<td align="center">P42336</td>
<td align="center">2ENQ</td>
<td align="center">Transferase</td>
<td align="center">&#x2212;5.20</td>
<td align="center">&#x2212;0.33</td>
</tr>
<tr>
<td align="center">BRCA2</td>
<td align="center">Breast cancer type 2 susceptibility protein</td>
<td align="center">P51587</td>
<td align="center">8BR9</td>
<td align="center">Antitumor protein</td>
<td align="center">&#x2212;5.14</td>
<td align="center">&#x2212;0.32</td>
</tr>
<tr>
<td align="center">ALB</td>
<td align="center">Albumin</td>
<td align="center">P02768</td>
<td align="center">7OV1</td>
<td align="center">Transport protein</td>
<td align="center">&#x2212;4.89</td>
<td align="center">&#x2212;0.31</td>
</tr>
<tr>
<td align="center">AR</td>
<td align="center">Androgen receptor</td>
<td align="center">P10275</td>
<td align="center">5JJM</td>
<td align="center">Transcription</td>
<td align="center">&#x2212;4.80</td>
<td align="center">&#x2212;0.30</td>
</tr>
<tr>
<td align="center">CTNNB1</td>
<td align="center" style="color:#0A0A0A">Catenin beta-1</td>
<td align="center">P35222</td>
<td align="center">1G3J</td>
<td align="center">Transcription</td>
<td align="center">&#x2212;4.78</td>
<td align="center">&#x2212;0.30</td>
</tr>
<tr>
<td align="center">BRCA1</td>
<td align="center">Breast cancer type 1 susceptibility protein</td>
<td align="center">P38398</td>
<td align="center">3COJ</td>
<td align="center">Antitumor protein</td>
<td align="center">&#x2212;4.75</td>
<td align="center">&#x2212;0.3</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The Metascape database was utilized to conduct a comprehensive analysis on the targets, revealing significant enrichment in GO terms and KEGG pathways (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>). The findings indicate that AC is essential in multiple biological functions such as the production of female reproductive cells, hormonal responses, sexual differentiation, regulation of hormone levels, and development of glands. Molecular functions include nuclear receptor activity, ATP-dependent activity, acting on DNA, transcription factor binding and monocarboxylic acid binding.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Network Pharmacology Predicts the Potential Mechanisms of &#x3b1;-Cyperone in Treating DOR. <bold>(A)</bold> GO enrichment analysis, including Biological Processes (BP), Cellular Components (CC), and Molecular Functions (MF). <bold>(B)</bold> KEGG enrichment analysis. Bubble size represents the number of enriched genes, and bubble color indicates the P-value. <bold>(C)</bold> Network maps of all crossed target genes in the top three pathways of the GO enrichment analysis were screened, and the top 20 key genes obtained by MCC algorithm.</p>
</caption>
<graphic xlink:href="fphar-16-1658536-g003.tif">
<alt-text content-type="machine-generated">Graph A shows a GO enrichment analysis with terms like &#x22;female gamete generation&#x22; and &#x22;sex differentiation&#x22; highlighted by dot size and color based on significance. Graph B illustrates a KEGG enrichment analysis with pathways such as &#x22;Pathways in cancer&#x22; presented similarly. Diagram C depicts molecular network analysis, contrasting a large interconnected network on the left with a highlighted subnetwork analyzed using the MCC algorithm on the right, featuring key nodes like AKT1 and ESR1.</alt-text>
</graphic>
</fig>
<p>Since DOR patients usually have abnormal sex hormone levels, and the results of GO enrichment suggest that the targets of AC action on DOR are closely related to hormone regulation, we focused on the targets enriched in the biological pathway of &#x201c;female gamete production, responses to hormone, sex differentiation&#x201d;. We uploaded all targets enriched in the aforementioned three pathways to the STRING database, followed by their importation into Cytoscape 3.10.1 software, and performed a network analysis using the MCC algorithm of the cytoHubba module, again selecting the top 20 key genes (<xref ref-type="fig" rid="F3">Figure 3C</xref>). After consolidating and eliminating duplicate entries from the initial pool of 20 crucial targets identified in two separate ways, a refined set of 22 key targets was derived for subsequent investigation. <xref ref-type="table" rid="T2">Table 2</xref> contains comprehensive data on the 22 primary objectives mentioned.</p>
</sec>
<sec id="s3-3">
<label>3.3</label>
<title>Validation of binding capacity between AC and 22 therapeutic targets by molecular docking</title>
<p>The molecular docking analysis was conducted to investigate the interactions between AC and a set of 22 specific genes. Employing AutoDock software, all the docking results were generated and displayed low binding energies (Delta G), indicating strong affinities between the compound and the targets (<xref ref-type="fig" rid="F4">Figure 4</xref>). The molecular docking results of AC with target proteins are shown in <xref ref-type="table" rid="T2">Table 2</xref>. Notably, all target proteins exhibited robust binding to AC with respective binding energy all &#x3c;0&#xa0;kcal/mol, which indicated that AC and each target can bind spontaneously, signifying their significant roles in the molecular mechanism of AC treatment on DOR. The visualizations of the lowest binding energies between each target and AC were created using Pymol. Furthermore, we also employed visualizations to depict the surface configurations of the target proteins in the molecular docking outcomes. Notably, it is evident that all AC molecules are situated within the active pockets of their respective proteins (<xref ref-type="sec" rid="s13">Supplementary Figure S1</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Molecular docking validation of the binding capacity between AC and targets, and shown the 3-dimensional map of the binding sites. AC is shown in violet. Target proteins are displayed as green. The places where AC and the target proteins are connected represent specific docking sites between AC and target proteins and are shown in magenta. AC:&#x3b1;-Cyperone.</p>
</caption>
<graphic xlink:href="fphar-16-1658536-g004.tif">
<alt-text content-type="machine-generated">Illustration showing molecular interactions of various proteins, labeled with abbreviations like MAP2K1, GSK3B, MAPK14, and others. Each protein interaction is highlighted with structural elements in different colors, including measurements in angstroms. The green background indicates the protein chain, with specific amino acids in pink and ligand binding sites in brown.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-4">
<label>3.4</label>
<title>Effect of AC on CTX-induced KGN injury model</title>
<p>The KGN cells were exposed to different levels of CTX or AC for 24&#xa0;h, after which the cell viability was evaluated using the CCK-8 assay (<xref ref-type="fig" rid="F5">Figures 5A&#x2013;B</xref>). The findings indicated that the IC50 of CTX on KGN was approximately 500&#x3bc;M, and AC concentrations below 80&#xa0;&#x3bc;M did not significantly affect KGN cell viability, suggesting that AC at concentrations below 80&#xa0;&#x3bc;M is non-cytotoxic to KGN cells, and 300&#x3bc;M CTX was selected for subsequent experiments. Following this, KGN cells were treated with gradient concentrations of AC for 6&#xa0;h and then induced with CTX (300&#xa0;&#x3bc;M) for 24&#xa0;h to establish DOR models (<xref ref-type="fig" rid="F5">Figure 5C</xref>). The cell viability was assessed using the CCK-8 assay, which indicated a significant reduction in cell viability observed in the CTX group compared to the NC group, while the viability of KGN cells significantly improved upon treatment with different concentrations of AC. Notably, even at the lowest effective concentration of AC, 40&#x3bc;M, the AC group showed a significant recovery effect similar to that of the NC group. Therefore, a concentration of 40&#xa0;&#x3bc;M AC was opted for further investigation. We examined the amount of AMH in the supernatants of the three groups of cells, NC, CTX, and AC, and the results showed that the secretion of AMH was significantly reduced in the CTX group compared with the NC group, while it was significantly increased in the 40&#xa0;&#x3bc;M AC treatment group (<xref ref-type="fig" rid="F5">Figure 5D</xref>). In addition, we examined the effects of AC on the ROS level and mitochondrial membrane potential (MMP) in CTX-treated KGN cells (<xref ref-type="fig" rid="F5">Figures 5E&#x2013;H</xref>). By DCFH staining, ROS levels were found to be raised in CTX-treated KGN cells. Treatment with AC for 24&#xa0;h significantly reduced ROS level. Decreased mitochondrial membrane potential, which can be reflected by the decreased fluorescence intensity ratio of JC-1 monomers to aggregates, is an early indicator of apoptosis (<xref ref-type="bibr" rid="B51">Smiley et al., 1991</xref>). In normal KGN cells, the JC-1 probe mainly aggregated in the mitochondrial matrix in the form of aggregates and emitted red fluorescence with little green fluorescence. By contrast, treatment with CTX for 24&#xa0;h significantly reduced red fluorescence and increased green fluorescence, suggesting the inhibited polymerization of JC-1 and mitochondrial membrane potential. Whereas, AC treatment moderated the mitochondrial depolarization induced by CTX. These proves the successful establishment of DOR cell model and the recovery of DOR granule cell function by AC.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Effect of AC on CTX-induced KGN injury model. <bold>(A)</bold> KGN cell viability was assayed by CCK-8 after treating KGN cells with graded concentrations of CTX alone for 24&#xa0;h. <bold>(B)</bold> KGN cell viability was assayed by CCK-8 after treating KGN cells with graded concentrations of AC alone for 24&#xa0;h. <bold>(C)</bold> The cells in the AC groups were first pretreated with a gradient concentration of AC for 6&#xa0;h, and then the cells in the CTX and AC groups were treated with CTX (300&#xa0;&#x3bc;M) for 24&#xa0;h. <bold>(D)</bold> The concentration of AMH in the supernatant of KGN cells. <bold>(E)</bold> Representative images of ROS levels as detected by DCFH staining in control, CTX and AC-treated KGN cells. <bold>(F)</bold> Fluorescence intensity of ROS signals. <bold>(G)</bold> Effects of AC on CTX-treated KGN cells mitochondrial membrane potential measured by JC-1 staining. Green fluorescence represents JC-1 monomers, whereas red fluorescence represents JC-1 aggregates. <bold>(H)</bold> Quantitative data of red/green fluorescence intensity ratio in the three groups &#x2a;p &#x3c; 0.05, &#x2a;&#x2a;&#x2a;&#x2a;p &#x3c; 0.0001 vs. NC group. &#x23;&#x23;p &#x3c; 0.01, &#x23;&#x23;&#x23;p &#x3c; 0.001 vs. CTX group.</p>
</caption>
<graphic xlink:href="fphar-16-1658536-g005.tif">
<alt-text content-type="machine-generated">Graphs and images showing the effects of &#x3B1;-Cyperone on cell viability and oxidative stress markers. Graph A shows cell viability decreasing with higher CTX concentrations; Graph B shows modest changes with &#x3B1;-Cyperone; Graph C shows combination effects; Graph D displays AMH levels. Images E and G reveal ROS and JC-1 fluorescence in different treatments. Graphs F and H illustrate mean fluorescence intensities for ROS and JC-1 under different conditions, highlighting significant differences marked by asterisks and hash symbols.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-5">
<label>3.5</label>
<title>Effect of AC on target proteins</title>
<p>We have identified the top 12 genes with the strongest binding affinity based on our molecular docking findings. To assess the mRNA statement levels of the target proteins, we utilized RT-qPCR analysis in both the NC and CTX groups. The outcomes obtained from our experiments (<xref ref-type="fig" rid="F6">Figure 6</xref>) demonstrated a significant increase in mRNA expression levels of MAPK14, ERBB2, CDH1, and ESR1 in the CTX group compared to the NC group. On the contrary, a significant reduction in the expression levels of MAP2K1, SRC, AKT1, ESR2, CYP19A1 and MAPK8 was observed in the CTX group compared to the NC group. AC treatment at 40&#xa0;&#x3bc;M completely reversed these abreeant expression patterns for MAP2K1, AKT1, ESR2, ERBB2, CDH1, CYP19A1, ESR1, and MAPK8, restoring transcript levels close to&#x2014;or even beyond&#x2014;those of healthy controls. These directional changes imply that AC re-balances oestrogen synthesis and survival signalling within granulosa cells, providing a plausible transcriptional basis for its observed improvement in ovarian function.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Effect of AC on target proteins. The mRNA expression levels of MAP2K1 <bold>(A)</bold>, GSK3B <bold>(B)</bold>, MAPK14 <bold>(C)</bold>, SRC <bold>(D)</bold>, AKT1 <bold>(E)</bold>, ESR2 <bold>(F)</bold>, ERBB2 <bold>(G)</bold>, CDH1 <bold>(H)</bold>, CYP19A1 <bold>(I)</bold>, ESR1 <bold>(J)</bold>, MAPK8 <bold>(K)</bold>, PARP1 <bold>(L)</bold>. AC treatment is able to reverse the abnormal gene expression of GSK3B, MAPK14, AKT1, ESR2, ERBB2, CYP19A1 and MAPK8 in the CTX group. NC: normal control, CTX: cyclophosphamide, AC: &#x3b1;-Cyperone, ns: P &#x3e; 0.05, &#x2a;P &#x3c; 0.05, &#x2a;&#x2a;P &#x3c; 0.01, &#x2a;&#x2a;&#x2a;P &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;P &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-16-1658536-g006.tif">
<alt-text content-type="machine-generated">Bar graphs labeled A to L show relative mRNA expression levels of various genes (MAP2K1, GSK3B, MAPK14, SRC, AKT1, ESR2, ERBB2, CDH1, CYP19A, ESR1, MAPK8, PARP1) in three conditions (CON, CTX, AC). Each graph varies in statistical significance, marked by asterisks indicating different levels of significance or non-significance (ns) between conditions.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-6">
<label>3.6</label>
<title>LiP&#x2013;MS analysis of identify AC-binding proteins in CTX-induced KGN cells</title>
<p>
<italic>In vitro</italic>, limited proteolysis&#x2013;mass spectrometry (LiP&#x2013;MS) has provided a way to observe changes in both protein abundances and structures on a proteome-wide scale. We extracted whole-cell protein samples from CTX-induced KGN cells, divided the samples into two aliquots, and one sample was incubated with AC for 24&#xa0;h. Two samples were treated with proteinase K (PK), and standard sample preparation was performed on two duplicate samples. All peptides were subjected to liquid chromatography-tandem MS (LC-MS/MS) in data independent acquisition (DIA) mode for DIA analysis (<xref ref-type="fig" rid="F7">Figure 7A</xref>, Created with <ext-link ext-link-type="uri" xlink:href="http://BioGDP.com">BioGDP.com</ext-link> (<xref ref-type="bibr" rid="B22">Jiang et al., 2025</xref>)).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>LiP&#x2013;MS analysis of identify AC-binding proteins in CTX-induced KGN cells&#xa0;<bold>(A)</bold>. Schematic diagram of Lip-MS principle (Created with <ext-link ext-link-type="uri" xlink:href="http://BioGDP.com">BioGDP.com</ext-link>). <bold>(B)</bold> The volcano plot of peptides in the two groups was plotted according to two factors: Fold change and P value (T-test). <bold>(C)</bold> Heatmap was used to identify differentially expressed peptides between the two groups. <bold>(D)</bold> KEGG analysis of differential peptides. <bold>(E&#x2013;G)</bold> Distribution of differentially abundant peptides between DOR and AC groups. Black is the theoretical complete sequence; Red is the detected upregulated sequence. The sequence of the detected downregulated changes is shown in blue.</p>
</caption>
<graphic xlink:href="fphar-16-1658536-g007.tif">
<alt-text content-type="machine-generated">LiP-MS analysis of identify AC-binding proteins in CTX-induced KGN cells.(A) The schematic diagram of Lip-MS principle. (B) The volcano plot of peptides in the two groups was plotted according to Fold change and P value (T-test).(C). Heatmap showing expression levels across different samples. (D). KEGG analysis of differential peptides. E-G. Distribution of differentially abundant peptides between DOR and AC groups.</alt-text>
</graphic>
</fig>
<p>In order to show the significant difference of peptides between the two groups, the volcano plot of peptides in the two groups was plotted according to two factors: Fold change and P value (T-test). The significantly downregulated peptides were marked in blue (FC &#x3c; 0.6 7 and p &#x3c; 0.05). Significantly upregulated peptides are marked in red (FC &#x3e; 1.5 and p &#x3c; 0.05) (<xref ref-type="fig" rid="F7">Figure 7B</xref>). The asymmetric cut-offs were chosen to account for the higher technical variability observed in low-abundance peptides. Hierarchical Cluster was used to group and classify the differentially expressed peptides of the two groups, and the Heatmap was displayed. Based on the similarity basis, in the clustering grouping results, the data pattern similarity within the group is generally high, while the data pattern similarity between the groups is low, so the groups can be effectively distinguished. According to the screening criteria of fold change &#x3e;1.5 times and P value &#x3c; 0.05 (T-test or other), the significantly differentially expressed peptides could effectively separate the comparison groups (<xref ref-type="fig" rid="F7">Figure 7C</xref>). In order to reveal the overall metabolic pathway enrichment characteristics of proteins corresponding to all differentially abundant peptides, proteins corresponding to all differentially abundant peptides were compared with all proteins of reference species (or all proteins identified experimentally) by KEGG annotation results (<xref ref-type="fig" rid="F7">Figure 7D</xref>). The results showed that, the proteins corresponding to the differentially abundant peptides between the two groups were significantly enriched in Regulation of actin cytoskeleton, Focal adhesion, Proteoglycans in cancer, and Cytoskeleton in muscle cells and other pathways.</p>
<p>Based on the principle of limited enzyme digestion method to find small molecule binding targets, if the abundance of the long peptide of a sequence can be detected at the same time, and the abundance of the corresponding short peptide can be detected, or the short peptide on the corresponding sequence cannot be detected, it means that the sequence may be closed due to the binding of drugs, and the sequence is relatively likely to be the target sequence. By corresponding all detected peptides to the complete sequence of the protein, the situation of peptides with differential abundance on the protein and their position on the sequence can be visualized. We found that among the top three proteins with the highest binding energies in the molecular docking experiment (MAP2K1, MAPK14 and GSK3B, with PG. Cscore (50, 47 and 25, respectively) far above the background threshold (5), indicating the strongest intracellular affinity), significantly upregulated peptides could be detected, while no corresponding significantly downregulated peptides could be detected (<xref ref-type="fig" rid="F7">Figures 7E&#x2013;G</xref>). It can be understood that in the granule cells of the DOR group, these three proteins were digested into extremely short peptides so that they could not be detected, while in the cells of the AC-treated group, these three proteins could not be digested after binding to AC, so that the significantly upregulated long peptides could be detected. In other words, MAP2K1, MAPK14 and GSK3B may be the key targets of AC binding.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<label>4</label>
<title>Discussion</title>
<p>The global decline in birth rates has intensified the infertility burden, with reproductive aging occurring at ever-younger ages. (<xref ref-type="bibr" rid="B39">Luo et al., 2021</xref>). Central to this trend is diminished ovarian reserve (DOR), a condition characterized by reduced oocyte quantity and quality that underlies &#x223c;20% of ovarian disorders (<xref ref-type="bibr" rid="B40">Practice Committee of the American Society for Reproductive, 2012</xref>), 10% of general infertility and 31% of IVF cases. Without timely intervention, DOR can rapidly advance to premature ovarian failure (POF), underscoring the urgent need for effective therapeutic strategies. (<xref ref-type="bibr" rid="B64">Zhang et al., 2023</xref>; <xref ref-type="bibr" rid="B36">Lu et al., 2014</xref>; <xref ref-type="bibr" rid="B8">Christodoulaki et al., 2021</xref>).</p>
<p>Chronic inflammation and oxidative stress are now recognized drivers of DOR. Previous studies have demonstrated that administration of lipopolysaccharide (LPS) to mammals leads to hormonal dysregulation, reduced ovarian reserve, and infertility (<xref ref-type="bibr" rid="B33">Liebers et al., 2008</xref>). LPS, a widely used inflammatory trigger, suppresses estradiol synthesis, downregulates gonadotropin receptors and CYP19A1, and activates p38/NF-&#x3ba;B/JNK signaling in granulosa cells (GCs), reducing estradiol output and cell viability. These changes culminate in ovarian inflammation, fibrosis and GC apoptosis&#x2014;changes that faithfully recapitulate the DOR phenotype in mice. (<xref ref-type="bibr" rid="B49">Shen et al., 2023</xref>; <xref ref-type="bibr" rid="B41">Magata et al., 2014</xref>; <xref ref-type="bibr" rid="B53">Sominsky et al., 2013</xref>; <xref ref-type="bibr" rid="B50">Shimizu et al., 2012</xref>; <xref ref-type="bibr" rid="B18">Herath et al., 2007</xref>). Because GCs constitute the largest steroidogenic population in the ovary and create the microenvironment required for follicle growth and oocyte maturation, their dysfunction directly compromises female fertility.</p>
<p>&#x3b1;-Cyperone, a major bioactive constituent of traditional Chinese medicines for gynecological disorders, has confirmed anti-inflammatory and antioxidant effects across multiple diseases (<xref ref-type="bibr" rid="B56">Taheri et al., 2021</xref>; <xref ref-type="bibr" rid="B21">Huang et al., 2023</xref>; <xref ref-type="bibr" rid="B34">Liu et al., 2019</xref>; <xref ref-type="bibr" rid="B45">Pei et al., 2020</xref>). Given the role of oxidative stress in the initiation and development of DOR, we postulate that &#x3b1;-Cyperone might exert a function in attenuating the decline of ovarian reserve and safeguarding ovarian function via its anti-inflammatory and antioxidant mechanisms. Consequently, we adopted the methodology of network pharmacology to predict the potential targets of &#x3b1;-Cyperone in the management of DOR. Yet our network-pharmacology analysis unexpectedly linked its potential efficacy in DOR to hormone-metabolism hubs rather than to classical oxidative-stress pathways. To dissect this paradigm, we substituted LPS with cyclophosphamide (CTX)&#x2014;a DNA-alkylating agent that injures granulosa cells (GCs) without evoking overt inflammation&#x2014;to exclude confounding antioxidant/anti-inflammatory effects. For this purpose, human KGN cells were pretreated with &#x3b1;-Cyperone (20&#xa0;&#x3bc;M, 6&#xa0;h) prior to CTX exposure, ensuring that any protective effect reflected preconditioning rather than post-injury rescue. Under this non-inflammatory DOR paradigm, &#x3b1;-Cyperone significantly restored AMH secretion, reduced ROS levels, stabilized mitochondrial membrane potential and improved cell viability. These data demonstrate that &#x3b1;-Cyperone preconditioning suffices to safeguard GC function against CTX-induced DOR injury, operating downstream&#x2014;or in parallel to&#x2014;oxidative stress and mitochondrial damage. The findings validate the hormone-centric prediction pipeline and position &#x3b1;-Cyperone as a metabolic modulator of ovarian reserve, warranting deeper dissection of its steroidogenic targets.</p>
<p>To further investigate the specific sites where &#x3b1;-Cyperone exerts its aforementioned functions, we conducted molecular docking validation. Generally, evaluating the outcomes of molecular docking primarily involves determining the minimum binding free energy (Delta G). Lower binding free energies (&#x394;G) indicate tighter, more stable complexes (<xref ref-type="bibr" rid="B5">Chen et al., 2023</xref>); accordingly, the top-ranked poses of AC against MAP2K1, MAPK14 and GSK3B exhibited robust negative &#x394;G values. These <italic>in silico</italic> predictions were corroborated by qPCR and LiP-MS, collectively implicating AC binding to these three kinases as a key mechanism for alleviating DOR.</p>
<p>MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1) and MAPK14 (c-Jun N-terminal kinase) &#x2014;core kinases of the stress-activated MAPK cascade&#x2014;relay oxidative and inflammatory insults to the nucleus, driving granulosa-cell (GC) apoptosis and follicular depletion in DOR (<xref ref-type="bibr" rid="B16">He et al., 2020</xref>; <xref ref-type="bibr" rid="B54">Sun et al., 2021</xref>). Our docking and Lip-MS data show that &#x3b1;-cyperone binds directly to both proteins, restores their CTX-suppressed transcript levels (<xref ref-type="fig" rid="F6">Figures 6</xref>, <xref ref-type="fig" rid="F7">7</xref>) and rapidly reduces ROS, providing a molecular explanation for the parallel recovery of AMH and mitochondrial membrane potential (<xref ref-type="fig" rid="F5">Figure 5</xref>). Glycogen synthase kinase three beta (GSK3B), the third validated target, acts as a master switch that links Wnt, PI3K/AKT and NF-&#x3ba;B signaling to steroidogenesis and early embryogenesis (<xref ref-type="bibr" rid="B35">Liu et al., 2024</xref>; <xref ref-type="bibr" rid="B63">Zhang et al., 2022</xref>; <xref ref-type="bibr" rid="B26">Kang et al., 2025</xref>; <xref ref-type="bibr" rid="B1">Ahmadnia et al., 2024</xref>; <xref ref-type="bibr" rid="B11">Fu et al., 2023</xref>; <xref ref-type="bibr" rid="B32">Liao et al., 2025</xref>). Although AC occupies the catalytic pocket of GSK3B (<xref ref-type="sec" rid="s13">Supplementary Figure S1</xref>) and reverses CTX-induced GC dysfunction, GSK3B mRNA levels remain unchanged (<xref ref-type="fig" rid="F6">Figure 6</xref>), implying post-translational control: diminished kinase activity would stabilize &#x3b2;-catenin, enhance CYP19A1 transcription and suppress NF-&#x3ba;B-driven inflammation, all of which favor follicle survival (<xref ref-type="bibr" rid="B1">Ahmadnia et al., 2024</xref>; <xref ref-type="bibr" rid="B32">Liao et al., 2025</xref>).</p>
<p>In addition to the three targets confirmed by Lip-MS, seven others (MAPK8, AKT1, ESR1/ESR2, ERBB2, CDH1 and CYP19A1) responded to AC at the transcript level. We propose the following scenario, grounded on published signalling cascades. CTX-metabolite 4-HC inflicts DNA damage, represses mTOR and PI3K-AKT activity, their downregulation lowers AKT survival signalling and dampens the parallel JNK (MAPK8) and ERK (MAP2K1) cascades, collectively reducing the transcription of oestrogen receptor ESR2 and of the oestrogen-synthesising enzyme CYP19A1 (<xref ref-type="bibr" rid="B42">Mani et al., 2010</xref>; <xref ref-type="bibr" rid="B3">Baddela et al., 2025</xref>), leading to decreased granulosa-cell proliferation and oestradiol production&#x2014;hallmarks of diminished ovarian reserve. Concurrently, cellular stress elicits a compensatory increase in growth-factor receptors and epithelial-mesenchymal transition genes, explaining the transient rise in ERBB2, CDH1 and ESR1 (<xref ref-type="bibr" rid="B3">Baddela et al., 2025</xref>; <xref ref-type="bibr" rid="B60">Xu et al., 2025</xref>). &#x3b1;-Cyperone has been reported to downregulate COX-2 and IL-6, to inhibit NF-&#x3ba;B signalling, and to re-activate the MAPK module, thereby restoring MAP2K1 expression and MAPK8 activity that drive granulosa-cell proliferation and differentiation (<xref ref-type="bibr" rid="B15">He et al., 2013</xref>; <xref ref-type="bibr" rid="B38">Luo et al., 2012</xref>; <xref ref-type="bibr" rid="B25">Jung et al., 2013</xref>). Concurrently, AC boosts the Akt/Nrf2/HO-1 axis, which rescues AKT1 expression, enhances antioxidant capacity and cell survival (<xref ref-type="bibr" rid="B62">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="B6">Chen et al., 2025</xref>), and indirectly increases ESR2 and CYP19A1 transcription, raising intra-follicular oestradiol (<xref ref-type="bibr" rid="B42">Mani et al., 2010</xref>). The relieved NF-&#x3ba;B drive allows ERBB2, CDH1 and ESR1 to return to baseline. This sequence integrates the qPCR changes into a coherent biological framework; detailed mechanistic validation is under way and will be reported separately.</p>
<p>Consequently, &#x3b1;-Cyperone may be a promising pharmacological agent that comprehensively regulates the aforementioned therapeutic targets in order to counteract the development of DOR. Derived from <italic>Cyperus rotundus L.</italic>&#x2014;a common culinary spice that deodorises fish and meat while conferring anti-oxidant and anti-inflammatory benefits (<xref ref-type="bibr" rid="B21">Huang et al., 2023</xref>) &#x2014;it is ideally positioned for early-stage dietary supplementation to delay ovarian reserve decline.</p>
<p>Although the parent herb Xiangfu (<italic>Cyperi Rhizoma L</italic>.) has long been used in gynaecology, the therapeutic value of &#x3b1;-cyperone in DOR has not been explored. Here, we integrate network pharmacology, molecular docking, <italic>in vitro</italic> assays and Lip-MS to identify and validate MAP2K1, MAPK14 and GSK3B as direct AC-binding targets in granulosa cells&#x2014;an approach not previously reported. We further show that a 40&#xa0;&#xb5;M dose of AC restores AMH secretion, mitochondrial membrane potential and viability while suppressing ROS in a CTX-induced DOR model, revealing an antioxidant, pro-survival role for AC within the ovarian micro-environment. These findings extend the biological repertoire of AC to female reproductive biology and provide a new lead compound with defined targets for DOR intervention; mechanistic and translational studies now in progress will benchmark AC against existing therapeutics and refine its clinical dosing rationale.</p>
<p>However, the Lip-MS strategy used here is inherently constrained by detection thresholds. The method relies on the generation and ionisation of proteolytic peptides; consequently, low-abundance, transient, or weak-affinity interactors (Kd &#x3e; 10&#xa0;&#xb5;M) are frequently missed, leading to false negatives. In addition, stochastic cleavage by proteinase K and variable peptide ionisation efficiency introduce background noise that can mask genuine AC-binding proteins. Rather than performing an unbiased intersection of all MS-detected bands with the 257 <italic>in silico</italic> candidates&#x2014;which would dilute specificity with low-confidence peptides&#x2014;we adopted a &#x201c;filter-then-validate&#x201d; pipeline: high-confidence targets derived from integrated network pharmacology (PubChem, PharmMapper, SwissTargetPrediction) plus molecular docking were subjected to Lip-MS, and only those yielding robust spectral counts (MAP2K1, GSK3B, MAPK14) were advanced for functional confirmation. This sequence minimises false positives while conserving experimental resources, and is widely employed in target-deconvolution studies to maintain both sensitivity and interpretability.</p>
<p>In addition, this study still has the following limitations. First, the study is explicitly hypothesis-generating, driven by network pharmacology: candidate targets were prioritized through <italic>in silico</italic> screening, molecular docking and Lip-MS, although network pharmacology, molecular docking and Lip-MS convergently nominated MAP2K1, MAPK14 and GSK3B as AC-binding targets, direct evidence that the compound activates or inhibits these kinases is still missing; Next, we are going to quantifying catalytic activity and phospho-status by SPR and Western blot, and we will initiate ChIP-qPCR to determine whether AC-induced kinase modulation alters transcription-factor occupancy on the promoters of MAPK8, AKT1, ESR2, CYP19A1, etc. Second, Although MAP2K1, MAPK14 and GSK3B appear able to bind &#x3b1;-cyperone and restore granulosa-cell function, definitive validation will require larger independent cohorts, gain-/loss-of-function models and quantitative proteomic analysis of patient follicular fluid. Third, &#x3b1;-Cyperone has not been benchmarked against established DOR therapeutics or tested in combination regimens; thus, its standalone or additive value beyond the observed antioxidant cytoprotection must be established through more comprehensive cellular, <italic>in vivo</italic> and clinical studies. Finally, the optimal dose, bioavailability and long-term cost-effectiveness of &#x3b1;-Cyperone remain undefined, and clinical translation may necessitate non-volatile delivery platforms such as engineered exosomes or nanoparticle systems. These issues are currently being actively studied and will be answered in subsequent research.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<label>5</label>
<title>Conclusion</title>
<p>Our research utilizes a comprehensive methodology that includes network pharmacology, bioinformatics analysis, molecular docking simulation, <italic>in vitro</italic> cell assessments, and Lip-MS to extensively screen potential therapeutic targets for &#x3b1;-Cyperone against DOR. Furthermore, we demonstrate the protective effect of &#x3b1;-Cyperone on DOR granule cell function <italic>in vitro</italic>. The mechanism may be due to the targeted binding ability of AC to domains of MAP2K1, MAPK14 and GSK3B. These findings provide valuable insights into potential therapeutic targets for &#x3b1;-Cyperone against DOR and establish a solid theoretical foundation for its application in DOR treatment.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are publicly available. Lip-MS raw data: [ProteomeXchange Consortium, dataset identifier PXD072555]. &#x03B1;-Cyperone chemical structure: PubChem CID 6452086 (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/6452086">https://pubchem.ncbi.nlm.nih.gov/compound/6452086</ext-link>). Protein sequences/structures: UniProt IDs listed in Table 2 (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org">https://www.uniprot.org</ext-link>). Further inquiries can be directed to the corresponding author(s).</p>
</sec>
<sec sec-type="ethics-statement" id="s7">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.</p>
</sec>
<sec sec-type="author-contributions" id="s8">
<title>Author contributions</title>
<p>JG: Conceptualization, Methodology, Investigation, Writing &#x2013; original draft. XY: Data curation, Formal Analysis, Writing &#x2013; review and editing, Investigation. XC: Validation, Writing &#x2013; review and editing. RH: Writing &#x2013; review and editing, Resources, Supervision. HG: Writing &#x2013; review and editing, Resources, Funding acquisition, Project administration.</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s11">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s12">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="s13">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2025.1658536/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2025.1658536/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material>
<label>SUPPLEMENTARY FIGURE S1</label>
<caption>
<p>Molecular docking validation of the binding capacity between AC and targets, and shows the surface structure of the target protein and the active pocket where AC is located. AC is shown in violet. The surface structure of the target protein is shown in gray. AC:&#x3b1;-Cyperone.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>SUPPLEMENTARY FIGURE S2</label>
<caption>
<p>Nodes in the DOR<bold>(A)</bold> and AC <bold>(B)</bold> PPI networks were colour-coded by source database (purple &#x3d; PharmMapper, green &#x3d; SwissTargetPrediction, blue &#x3d; OMIM, pink &#x3d; GeneCards).</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image2.tif" id="SM1" mimetype="application/tif" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.tif" id="SM2" mimetype="application/tif" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1006125/overview">Subhash Chander</ext-link>, Amity University Haryana, India</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/51748/overview">Inamul Hasan Madar</ext-link>, Yenepoya (deemed to be University), India</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1464382/overview">Akash Acharyya</ext-link>, Bose Institute, India</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2162497/overview">Yefang Huang</ext-link>, Hospital of Chengdu University of Traditional Chinese Medicine, China</p>
</fn>
</fn-group>
<fn-group>
<fn fn-type="abbr" id="abbrev1">
<label>Abbreviations:</label>
<p>DOR, Diminished ovarian reserve; CR, Cyperi Rhizoma; AC, &#x03B1;-Cyperone; Lip-MS, Limited proteolysis&#x2013;mass spectrometry; LPS, Lipopolysaccharide; NC, The normal control; AFC, Antral Follicle Count; PPI, Protein-Protein Interaction; FSH, Follicle stimulating hormone; AMH, Anti-Mullerian hormone; OMIM, Online Mendelian Inheritance in Man; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, Biological processes; CC, Cellular components; MF, Molecular functions.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmadnia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Montazeri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dashti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sheikhha</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Lotfi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Expression of steroidogenesis pathway genes in cumulus cells from women with diminished ovarian reserve after gonadotropin administration: a case-control study</article-title>. <source>Int. J. Reprod. Biomed.</source> <volume>22</volume> (<issue>9</issue>), <fpage>701</fpage>&#x2013;<lpage>708</lpage>. <pub-id pub-id-type="doi">10.18502/ijrm.v22i9.17474</pub-id>
<pub-id pub-id-type="pmid">39618718</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amberger</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Bocchini</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Schiettecatte</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Hamosh</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>OMIM.org: Online mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders</article-title>. <source>Nucleic Acids Res.</source> <volume>43</volume>, <fpage>D789</fpage>&#x2013;<lpage>D798</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku1205</pub-id>
<pub-id pub-id-type="pmid">25428349</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baddela</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Michaelis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Koczan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Brenmoehl</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vanselow</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Comparative analysis of PI3K-AKT and MEK-ERK1/2 signaling-driven molecular changes in granulosa cells</article-title>. <source>Reproduction</source> <volume>169</volume> (<issue>2</issue>), <fpage>e240317</fpage>. <pub-id pub-id-type="doi">10.1530/REP-24-0317</pub-id>
<pub-id pub-id-type="pmid">39665647</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berman</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Westbrook</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gilliland</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>T. N.</given-names>
</name>
<name>
<surname>Weissig</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>The protein data bank</article-title>. <source>Nucleic Acids Res.</source> <volume>28</volume> (<issue>1</issue>), <fpage>235</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id>
<pub-id pub-id-type="pmid">10592235</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation</article-title>. <source>J. Transl. Med.</source> <volume>21</volume> (<issue>1</issue>), <fpage>380</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-023-04233-0</pub-id>
<pub-id pub-id-type="pmid">37308949</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Alpha-cyperone ameliorates renal fibrosis and inflammation in mice with chronic kidney disease <italic>via</italic> NF-kappaB and Akt/Nrf2/HO-1 pathways</article-title>. <source>Immunopharmacol. Immunotoxicol.</source> <volume>47</volume> (<issue>4</issue>), <fpage>460</fpage>&#x2013;<lpage>470</lpage>. <pub-id pub-id-type="doi">10.1080/08923973.2025.2507129</pub-id>
<pub-id pub-id-type="pmid">40415449</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chin</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. Y.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>cytoHubba: identifying hub objects and sub-networks from complex interactome</article-title>. <source>BMC Syst. Biol.</source> <volume>8</volume>, <fpage>S11</fpage>. <pub-id pub-id-type="doi">10.1186/1752-0509-8-S4-S11</pub-id>
<pub-id pub-id-type="pmid">25521941</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christodoulaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Roo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stoop</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Heindryckx</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Prospects of germline nuclear transfer in women with diminished Ovarian Reserve</article-title>. <source>Front. Endocrinol. (Lausanne)</source> <volume>12</volume>, <fpage>635370</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2021.635370</pub-id>
<pub-id pub-id-type="pmid">33692760</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Tumor necrosis factor alpha knockout increases fertility of mice</article-title>. <source>Theriogenology</source> <volume>75</volume> (<issue>5</issue>), <fpage>867</fpage>&#x2013;<lpage>876</lpage>. <pub-id pub-id-type="doi">10.1016/j.theriogenology.2010.10.029</pub-id>
<pub-id pub-id-type="pmid">21211832</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Souza</surname>
<given-names>F. H.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Yamakami</surname>
<given-names>L. Y.</given-names>
</name>
<name>
<surname>dos Santos Trindade Viana</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bonfa</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shinjo</surname>
<given-names>S. K.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Reduced ovarian reserve in patients with adult polymyositis</article-title>. <source>Clin. Rheumatol.</source> <volume>34</volume> (<issue>10</issue>), <fpage>1795</fpage>&#x2013;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1007/s10067-015-3064-1</pub-id>
<pub-id pub-id-type="pmid">26345632</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Tetrahedral framework nucleic acids enhance the chondrogenic potential of human umbilical cord mesenchymal stem cells <italic>via</italic> the PI3K/AKT axis</article-title>. <source>Regen. Biomater.</source> <volume>10</volume>, <fpage>rbad085</fpage>. <pub-id pub-id-type="doi">10.1093/rb/rbad085</pub-id>
<pub-id pub-id-type="pmid">37814675</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gene Ontology</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Gene Ontology Consortium: going forward</article-title>. <source>Nucleic Acids Res.</source> <volume>43</volume> (<issue>Database issue</issue>), <fpage>D1049</fpage>&#x2013;<lpage>D1056</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku1179</pub-id>
<pub-id pub-id-type="pmid">25428369</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gfeller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Grosdidier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wirth</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Daina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Michielin</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Zoete</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>SwissTargetPrediction: a web server for target prediction of bioactive small molecules</article-title>. <source>Nucleic Acids Res.</source> <volume>42</volume> (<issue>Web Server issue</issue>), <fpage>W32</fpage>&#x2013;<lpage>W38</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku293</pub-id>
<pub-id pub-id-type="pmid">24792161</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greene</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Patounakis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Segars</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Genetic associations with diminished ovarian reserve: a systematic review of the literature</article-title>. <source>J. Assist. Reprod. Genet.</source> <volume>31</volume> (<issue>8</issue>), <fpage>935</fpage>&#x2013;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1007/s10815-014-0257-5</pub-id>
<pub-id pub-id-type="pmid">24840722</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Q. J.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H. Q.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Q. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Xiang-Qi-Tang and its active components exhibit anti-inflammatory and anticoagulant properties by inhibiting MAPK and NF-kappaB signaling pathways in LPS-treated rat cardiac microvascular endothelial cells</article-title>. <source>Immunopharmacol. Immunotoxicol.</source> <volume>35</volume> (<issue>2</issue>), <fpage>215</fpage>&#x2013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.3109/08923973.2012.744034</pub-id>
<pub-id pub-id-type="pmid">23171279</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Using bioinformatics and metabolomics to identify altered granulosa cells in patients with diminished ovarian reserve</article-title>. <source>PeerJ</source> <volume>8</volume>, <fpage>e9812</fpage>. <pub-id pub-id-type="doi">10.7717/peerj.9812</pub-id>
<pub-id pub-id-type="pmid">32923184</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Identification of common and specific genes involved in mouse models of age-related and cyclophosphamide-induced diminished Ovarian Reserve</article-title>. <source>Reprod. Sci.</source> <volume>30</volume> (<issue>6</issue>), <fpage>1965</fpage>&#x2013;<lpage>1978</lpage>. <pub-id pub-id-type="doi">10.1007/s43032-022-01161-0</pub-id>
<pub-id pub-id-type="pmid">36587055</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herath</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Lilly</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>R. O.</given-names>
</name>
<name>
<surname>Dobson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bryant</surname>
<given-names>C. E.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Ovarian follicular cells have innate immune capabilities that modulate their endocrine function</article-title>. <source>Reproduction</source> <volume>134</volume> (<issue>5</issue>), <fpage>683</fpage>&#x2013;<lpage>693</lpage>. <pub-id pub-id-type="doi">10.1530/REP-07-0229</pub-id>
<pub-id pub-id-type="pmid">17965259</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Efficient analysis of toxicity and mechanisms of environmental pollutants with network toxicology and molecular docking strategy: acetyl tributyl citrate as an example</article-title>. <source>Sci. Total Environ.</source> <volume>905</volume>, <fpage>167904</fpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2023.167904</pub-id>
<pub-id pub-id-type="pmid">37858827</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang da</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Lempicki</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source>Nat. Protoc.</source> <volume>4</volume> (<issue>1</issue>), <fpage>44</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id>
<pub-id pub-id-type="pmid">19131956</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>alpha-Cyperone protects dopaminergic neurons and inhibits neuroinflammation in LPS-induced Parkinson&#x27;s disease rat model <italic>via</italic> activating Nrf2/HO-1 and suppressing NF-kappaB signaling pathway</article-title>. <source>Int. Immunopharmacol.</source> <volume>115</volume>, <fpage>109698</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2023.109698</pub-id>
<pub-id pub-id-type="pmid">36634417</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics</article-title>. <source>Nucleic Acids Res.</source> <volume>53</volume> (<issue>D1</issue>), <fpage>D1670</fpage>&#x2013;<lpage>D1676</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkae973</pub-id>
<pub-id pub-id-type="pmid">39470721</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Bukulmez</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Potential roles of experimental reproductive technologies in infertile women with diminished ovarian reserve</article-title>. <source>J. Assist. Reprod. Genet.</source> <volume>38</volume> (<issue>10</issue>), <fpage>2507</fpage>&#x2013;<lpage>2517</lpage>. <pub-id pub-id-type="doi">10.1007/s10815-021-02246-6</pub-id>
<pub-id pub-id-type="pmid">34100154</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Ovarian reserve markers in premature ovarian insufficiency: within different clinical stages and different etiologies</article-title>. <source>Front. Endocrinol. (Lausanne)</source> <volume>12</volume>, <fpage>601752</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2021.601752</pub-id>
<pub-id pub-id-type="pmid">33815272</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Jun</surname>
<given-names>B. G.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K. T.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>M. S.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>alpha-Cyperone, isolated from the rhizomes of Cyperus rotundus, inhibits LPS-induced COX-2 expression and PGE2 production through the negative regulation of NFkappaB signalling in RAW 264.7 cells</article-title>. <source>J. Ethnopharmacol.</source> <volume>147</volume> (<issue>1</issue>), <fpage>208</fpage>&#x2013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2013.02.034</pub-id>
<pub-id pub-id-type="pmid">23500883</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>The SGK3/GSK3beta/beta-catenin signaling promotes breast cancer stemness and confers resistance to alpelisib therapy</article-title>. <source>Int. J. Biol. Sci.</source> <volume>21</volume> (<issue>6</issue>), <fpage>2462</fpage>&#x2013;<lpage>2475</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.104850</pub-id>
<pub-id pub-id-type="pmid">40303291</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Getting the most out of PubChem for virtual screening</article-title>. <source>Expert Opin. Drug Discov.</source> <volume>11</volume> (<issue>9</issue>), <fpage>843</fpage>&#x2013;<lpage>855</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2016.1216967</pub-id>
<pub-id pub-id-type="pmid">27454129</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thiessen</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gindulyte</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>PubChem Substance and Compound databases</article-title>. <source>Nucleic Acids Res.</source> <volume>44</volume> (<issue>D1</issue>), <fpage>D1202</fpage>&#x2013;<lpage>D1213</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id>
<pub-id pub-id-type="pmid">26400175</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Investigating the impact of local inflammation on granulosa cells and follicular development in women with ovarian endometriosis</article-title>. <source>Fertil. Steril.</source> <volume>112</volume> (<issue>5</issue>), <fpage>882</fpage>&#x2013;<lpage>891 e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2019.07.007</pub-id>
<pub-id pub-id-type="pmid">31551156</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Whole exome sequencing reveals novel variants associated with diminished ovarian reserve in young women</article-title>. <source>Front. Genet.</source> <volume>14</volume>, <fpage>1154067</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2023.1154067</pub-id>
<pub-id pub-id-type="pmid">37065482</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Study on the effects and mechanisms of Wenzhong Bushen Formula in improving ovarian reserve decline in mice based on network pharmacology</article-title>. <source>J. Ethnopharmacol.</source> <volume>324</volume>, <fpage>117756</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2024.117756</pub-id>
<pub-id pub-id-type="pmid">38218503</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Integrating network pharmacology, quantitative transcriptomic analysis, and experimental validation revealed the mechanism of cordycepin in the treatment of obesity</article-title>. <source>Front. Pharmacol.</source> <volume>16</volume>, <fpage>1571480</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2025.1571480</pub-id>
<pub-id pub-id-type="pmid">40438591</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liebers</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Raulf-Heimsoth</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bruning</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Health effects due to endotoxin inhalation (review)</article-title>. <source>Arch. Toxicol.</source> <volume>82</volume> (<issue>4</issue>), <fpage>203</fpage>&#x2013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-008-0290-1</pub-id>
<pub-id pub-id-type="pmid">18322674</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Suppression of NLRP3 and NF-kappaB signaling pathways by alpha-Cyperone <italic>via</italic> activating SIRT1 contributes to attenuation of LPS-induced acute lung injury in mice</article-title>. <source>Int. Immunopharmacol.</source> <volume>76</volume>, <fpage>105886</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2019.105886</pub-id>
<pub-id pub-id-type="pmid">31520990</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q. C.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Dysregulated Wnt/beta-catenin signaling confers resistance to cuproptosis in cancer cells</article-title>. <source>Cell Death Differ.</source> <volume>31</volume> (<issue>11</issue>), <fpage>1452</fpage>&#x2013;<lpage>1466</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-024-01341-2</pub-id>
<pub-id pub-id-type="pmid">38987382</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Low testosterone levels in women with diminished ovarian reserve impair embryo implantation rate: a retrospective case-control study</article-title>. <source>J. Assist. Reprod. Genet.</source> <volume>31</volume> (<issue>4</issue>), <fpage>485</fpage>&#x2013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1007/s10815-014-0186-3</pub-id>
<pub-id pub-id-type="pmid">24526354</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luderer</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Ovarian toxicity from reactive oxygen species</article-title>. <source>Vitam. Horm.</source> <volume>94</volume>, <fpage>99</fpage>&#x2013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-800095-3.00004-3</pub-id>
<pub-id pub-id-type="pmid">24388188</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>alpha-cyperone alleviates lung cell injury caused by Staphylococcus aureus <italic>via</italic> attenuation of alpha-hemolysin expression</article-title>. <source>J. Microbiol. Biotechnol.</source> <volume>22</volume> (<issue>8</issue>), <fpage>1170</fpage>&#x2013;<lpage>1176</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1202.02017</pub-id>
<pub-id pub-id-type="pmid">22713997</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Trends and challenges for population and health during population aging - china, 2015-2050</article-title>. <source>China CDC Wkly.</source> <volume>3</volume> (<issue>28</issue>), <fpage>593</fpage>&#x2013;<lpage>598</lpage>. <pub-id pub-id-type="doi">10.46234/ccdcw2021.158</pub-id>
<pub-id pub-id-type="pmid">34594944</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magata</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Lipopolysaccharide (LPS) inhibits steroid production in theca cells of bovine follicles <italic>in vitro:</italic> distinct effect of LPS on theca cell function in pre- and post-selection follicles</article-title>. <source>J. Reprod. Dev.</source> <volume>60</volume> (<issue>4</issue>), <fpage>280</fpage>&#x2013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1262/jrd.2013-124</pub-id>
<pub-id pub-id-type="pmid">24769841</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mani</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Fenwick</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wathes</surname>
<given-names>D. C.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>IGF1 induces up-regulation of steroidogenic and apoptotic regulatory genes <italic>via</italic> activation of phosphatidylinositol-dependent kinase/AKT in bovine granulosa cells</article-title>. <source>Reproduction</source> <volume>139</volume> (<issue>1</issue>), <fpage>139</fpage>&#x2013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1530/REP-09-0050</pub-id>
<pub-id pub-id-type="pmid">19819918</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navarro-Pando</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Alcocer-G&#xf3;mez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Castej&#xf3;n-Vega</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Navarro-Villar&#xe1;n</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cond&#xe9;s-Herv&#xe1;s</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mundi-Roldan</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Inhibition of the NLRP3 inflammasome prevents ovarian aging</article-title>. <source>Sci. Adv.</source> <volume>7</volume> (<issue>1</issue>), <fpage>eabc7409</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abc7409</pub-id>
<pub-id pub-id-type="pmid">33523841</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x27;Boyle</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Banck</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Morley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vandermeersch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hutchison</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Open Babel: an open chemical toolbox</article-title>. <source>J. Cheminform</source> <volume>3</volume>, <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>
<pub-id pub-id-type="pmid">21982300</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pei</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L. Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J. S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>alpha-Cyperone inhibits the proliferation of human cervical cancer HeLa cells <italic>via</italic> ROS-mediated PI3K/Akt/mTOR signaling pathway</article-title>. <source>Eur. J. Pharmacol.</source> <volume>883</volume>, <fpage>173355</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173355</pub-id>
<pub-id pub-id-type="pmid">32687921</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piazza</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kochanowski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cappelletti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fuhrer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Noor</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sauer</surname>
<given-names>U.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>A map of protein-metabolite interactions reveals principles of chemical communication</article-title>. <source>Cell</source> <volume>172</volume> (<issue>1-2</issue>), <fpage>358</fpage>&#x2013;<lpage>372 e23</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.12.006</pub-id>
<pub-id pub-id-type="pmid">29307493</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<collab>Practice Committee of the American Society for Reproductive</collab> (<year>2012</year>). <article-title>Testing and interpreting measures of ovarian reserve: a committee opinion</article-title>. <source>Fertil. Steril.</source> <volume>98</volume> (<issue>6</issue>), <fpage>1407</fpage>&#x2013;<lpage>1415</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2012.09.036</pub-id>
<pub-id pub-id-type="pmid">23095141</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Safran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dalah</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iny Stein</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shmoish</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>GeneCards Version 3: the human gene integrator</article-title>. <source>Database (Oxford)</source> <volume>2010</volume>, <fpage>baq020</fpage>. <pub-id pub-id-type="doi">10.1093/database/baq020</pub-id>
<pub-id pub-id-type="pmid">20689021</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senates</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>&#xc7;olak</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Erdem</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Ye&#x15f;il</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Co&#x15f;kunp&#x131;nar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>&#x15e;ahin</surname>
<given-names>&#xd6;.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Serum Anti-Mullerian hormone levels are lower in reproductive-age women with Crohn&#x27;s disease compared to healthy control women</article-title>. <source>J. Crohns Colitis</source> <volume>7</volume> (<issue>2</issue>), <fpage>e29</fpage>&#x2013;<lpage>e34</lpage>. <pub-id pub-id-type="doi">10.1016/j.crohns.2012.03.003</pub-id>
<pub-id pub-id-type="pmid">22472089</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Lipopolysaccharide accelerates tryptophan degradation in the ovary and the derivative kynurenine disturbs hormone biosynthesis and reproductive performance</article-title>. <source>J. Hazard Mater</source> <volume>458</volume>, <fpage>131988</fpage>. <pub-id pub-id-type="doi">10.1016/j.jhazmat.2023.131988</pub-id>
<pub-id pub-id-type="pmid">37418963</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miyauchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shirasuna</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bollwein</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Magata</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Murayama</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Effects of lipopolysaccharide (LPS) and peptidoglycan (PGN) on estradiol production in bovine granulosa cells from small and large follicles</article-title>. <source>Toxicol Vitro</source> <volume>26</volume> (<issue>7</issue>), <fpage>1134</fpage>&#x2013;<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2012.06.014</pub-id>
<pub-id pub-id-type="pmid">22771338</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smiley</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>Reers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mottola-Hartshorn</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>T. W.</given-names>
</name>
<etal/>
</person-group> (<year>1991</year>). <article-title>Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>88</volume> (<issue>9</issue>), <fpage>3671</fpage>&#x2013;<lpage>3675</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.88.9.3671</pub-id>
<pub-id pub-id-type="pmid">2023917</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snider</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Obesity induces ovarian inflammation and reduces oocyte quality</article-title>. <source>Reproduction</source> <volume>158</volume> (<issue>3</issue>), <fpage>R79</fpage>&#x2013;<lpage>R90</lpage>. <pub-id pub-id-type="doi">10.1530/REP-18-0583</pub-id>
<pub-id pub-id-type="pmid">30999278</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sominsky</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sobinoff</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Jobling</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Pye</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Hodgson</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Immune regulation of ovarian development: programming by neonatal immune challenge</article-title>. <source>Front. Neurosci.</source> <volume>7</volume>, <fpage>100</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2013.00100</pub-id>
<pub-id pub-id-type="pmid">23781169</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Decreased expression of IDH1 by chronic unpredictable stress suppresses proliferation and accelerates senescence of granulosa cells through ROS activated MAPK signaling pathways</article-title>. <source>Free Radic. Biol. Med.</source> <volume>169</volume>, <fpage>122</fpage>&#x2013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.04.016</pub-id>
<pub-id pub-id-type="pmid">33865962</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gable</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Nastou</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>Lyon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kirsch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pyysalo</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>. <source>Nucleic Acids Res.</source> <volume>49</volume> (<issue>D1</issue>), <fpage>D605</fpage>&#x2013;<lpage>D612</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa1074</pub-id>
<pub-id pub-id-type="pmid">33237311</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taheri</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Herrera-Bravo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huala</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Salazar</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Sharifi-Rad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Akram</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Cyperus spp.: a review on phytochemical composition, biological activity, and health-promoting effects</article-title>. <source>Oxid. Med. Cell Longev.</source> <volume>2021</volume>, <fpage>4014867</fpage>. <pub-id pub-id-type="doi">10.1155/2021/4014867</pub-id>
<pub-id pub-id-type="pmid">34539969</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>UniProt</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>UniProt: the Universal Protein Knowledgebase in 2023</article-title>. <source>Nucleic Acids Res.</source> <volume>51</volume> (<issue>D1</issue>), <fpage>D523</fpage>&#x2013;<lpage>D531</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac1052</pub-id>
<pub-id pub-id-type="pmid">36408920</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database</article-title>. <source>Nucleic Acids Res.</source> <volume>45</volume> (<issue>W1</issue>), <fpage>W356</fpage>&#x2013;<lpage>W360</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx374</pub-id>
<pub-id pub-id-type="pmid">28472422</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>wSDTNBI: a novel network-based inference method for virtual screening</article-title>. <source>Chem. Sci.</source> <volume>13</volume> (<issue>4</issue>), <fpage>1060</fpage>&#x2013;<lpage>1079</lpage>. <pub-id pub-id-type="doi">10.1039/d1sc05613a</pub-id>
<pub-id pub-id-type="pmid">35211272</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Intrinsic differences in mTOR activity mediates lineage-specific responses to cyclophosphamide in mouse and human granulosa cells</article-title>. <source>J. Ovarian Res.</source> <volume>18</volume> (<issue>1</issue>), <fpage>49</fpage>. <pub-id pub-id-type="doi">10.1186/s13048-025-01627-0</pub-id>
<pub-id pub-id-type="pmid">40069773</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Ovarian IL-1alpha and IL-1beta levels are associated with primary ovarian insufficiency</article-title>. <source>Int. J. Clin. Exp. Pathol.</source> <volume>11</volume> (<issue>9</issue>), <fpage>4711</fpage>&#x2013;<lpage>4717</lpage>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/31949872">https://www.ncbi.nlm.nih.gov/pubmed/31949872</ext-link>.</comment>
<pub-id pub-id-type="pmid">31949872</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>alpha-Cyperone (CYP) down-regulates NF-kappaB and MAPKs signaling, attenuating inflammation and extracellular matrix degradation in chondrocytes, to ameliorate osteoarthritis in mice</article-title>. <source>Aging (Albany NY)</source> <volume>13</volume> (<issue>13</issue>), <fpage>17690</fpage>&#x2013;<lpage>17706</lpage>. <pub-id pub-id-type="doi">10.18632/aging.203259</pub-id>
<pub-id pub-id-type="pmid">34237707</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L. Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D. D.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Hydroxy-alpha-sanshool isolated from Zanthoxylum bungeanum Maxim. has antidiabetic effects on high-fat-fed and streptozotocin-treated mice <italic>via</italic> increasing glycogen synthesis by regulation of PI3K/Akt/GSK-3beta/GS signaling</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>1089558</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.1089558</pub-id>
<pub-id pub-id-type="pmid">36582530</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q. L.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>X. S.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Treatment progress in diminished ovarian reserve: western and Chinese medicine</article-title>. <source>Chin. J. Integr. Med.</source> <volume>29</volume> (<issue>4</issue>), <fpage>361</fpage>&#x2013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1007/s11655-021-3353-2</pub-id>
<pub-id pub-id-type="pmid">35015221</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pache</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khodabakhshi</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Tanaseichuk</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title>. <source>Nat. Commun.</source> <volume>10</volume> (<issue>1</issue>), <fpage>1523</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id>
<pub-id pub-id-type="pmid">30944313</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</article>